Windtree Therapeutics (WINT) S-1 21 Jan 20 2019 Q3 IPO registration Financial data

Document And Entity Information

Document And Entity Information	9 Months Ended
	Sep. 30, 2019
Document Information [Line Items]
Entity Registrant Name	WINDTREE THERAPEUTICS INC /DE/
Entity Central Index Key	0000946486
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	true
Document Type	S-1
Document Period End Date	Sep. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3
Amendment Flag	false

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Current Assets:
Cash and cash equivalents	$ 11,187,000	$ 1,815,000
Available-for-sale marketable securities	13,959,000
Prepaid expenses and other current assets	507,000	422,000
Total current assets	25,653,000	2,237,000
Property and equipment, net	802,000	885,000
Restricted cash	171,000	225,000
Indefinite intangible asset	77,090,000
Goodwill	15,682,000
Total assets	119,398,000	3,347,000
Current Liabilities:
Accounts payable	3,420,000	2,324,000
Collaboration and device development payable, net	2,576,000	4,418,000
Accrued Liabilities, Current, Total	6,465,000	4,134,000
Deferred revenue - current portion	198,000	884,000
Loan payable	7,974,000
Total current liabilities	20,633,000	11,760,000
Restructured debt liability - contingent milestone payments	15,000,000	15,000,000
Deferred revenue - non-current portion		407,000
Deferred tax liabilities	15,476,000
Other liabilities	175,000	100,000
Total liabilities	51,284,000	27,267,000
Stockholders' Equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; 0 shares and 2,701 shares issued and outstanding at December 31, 2018 and December 31, 2017, respectively	0	0
Common stock, $0.001 par value; 120,000,000 shares authorized at December 31, 2018 and December 31, 2017; 32,133,263 and 3,227,495 shares issued at December 31, 2018 and December 31, 2017, respectively; 32,133,189 shares and 3,227,421 shares outstanding at December 31, 2018 and December 31, 2017, respectively	32,000	3,000
Additional paid-in capital	728,783,000	616,245,000
Accumulated deficit	(657,647,000)	(637,114,000)
Treasury stock (at cost); 74 shares	(3,054,000)	(3,054,000)
Total stockholders' equity	68,114,000	(23,920,000)
Total liabilities & stockholders' equity	$ 119,398,000	$ 3,347,000

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares	Sep. 30, 2019	Dec. 31, 2018	Dec. 31, 2017	Feb. 15, 2017
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0	2,701
Preferred stock, shares outstanding (in shares)	0	0	2,701
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	120,000,000	120,000,000	120,000,000
Common stock, shares issued (in shares)	32,188,929	32,133,263	3,227,495
Common stock, shares outstanding (in shares)	32,188,855	32,133,189	3,227,421
Treasury stock, shares (in shares)	74	74	74

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended											9 Months Ended		12 Months Ended
	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
Total revenues				$ 304	$ 229	$ 1,051	$ 204	$ 102	$ 17	$ 1,147	$ 219	$ 198	$ 1,484	$ 1,788	$ 1,485
Expenses:
Research and development	3,792			2,368	2,197	2,879	3,118	2,418	3,062	5,483	6,413	10,547	8,194	10,562	17,376
General and administrative	3,395			2,787	1,500	1,208	1,926	1,182	1,749	1,804	1,922	9,990	4,634	7,421	6,657
Total operating expenses	7,187			5,155	3,697	4,087	5,044	3,600	4,811	7,287	8,335	20,537	12,828	17,983	24,033
Operating loss	(7,187)			(4,851)	(3,468)	(3,036)	(4,840)	(3,498)	(4,794)	(6,140)	(8,116)	(20,339)	(11,344)	(16,195)	(22,548)
Other income / (expense):
Net loss on debt extinguishment														(3,345)
Gain on debt restructuring															5,824
Interest income	25				1							124	9	15	12
Interest expense	(105)				(460)							(358)	(642)	(1,409)	(1,863)
Other income, net	141											473	486	401	129
Other income / (expense), net	61				(459)							239	(147)	(4,338)	4,102
Net loss	$ (7,126)	$ (6,437)	$ (6,537)	(9,042)	(3,927)	(3,052)	(4,512)	2,473	(5,443)	(6,752)	(8,724)	$ (20,100)	$ (11,491)	(20,533)	(18,446)
AEROSURF warrant dividend				(12,505)										(12,505)
Deemed dividend on Series A preferred stock				(1,718)					(2,234)	(532)	(3,604)			(1,718)	(6,370)
Net loss attributable to common shareholders				(23,265)	$ (3,927)	(3,052)	(4,512)	2,473	(7,677)	(7,284)	(12,328)			$ (34,756)	$ (24,816)
Net loss per common share
Basic and diluted (in dollars per share)	$ (0.22)				$ (1.04)							$ (0.62)	$ (3.21)	$ (7.74)	$ (24.14)
Weighted average number of common shares outstanding
Basic and diluted (in shares)	32,189,000				3,769,000							32,173,000	3,585,000	4,493	1,028
Grant [Member]
License revenue with affiliate					$ 70								$ 765	$ 765	$ 1,383
License [Member]
License revenue with affiliate				$ 304	$ 159	$ 356	$ 204	$ 102				$ 198	$ 719	$ 1,023	$ 102

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity - USD ($)	Private Placement [Member]Preferred Stock [Member]	Private Placement [Member]Common Stock [Member]	Private Placement [Member]Additional Paid-in Capital [Member]	Private Placement [Member]Retained Earnings [Member]	Private Placement [Member]Treasury Stock [Member]	Private Placement [Member]	Share Purchase Agreement [Member]Preferred Stock [Member]	Share Purchase Agreement [Member]Common Stock [Member]	Share Purchase Agreement [Member]Additional Paid-in Capital [Member]	Share Purchase Agreement [Member]Retained Earnings [Member]	Share Purchase Agreement [Member]Treasury Stock [Member]	Share Purchase Agreement [Member]	Share Purchase Agreement, April 2018 [Member]Preferred Stock [Member]	Share Purchase Agreement, April 2018 [Member]Common Stock [Member]	Share Purchase Agreement, April 2018 [Member]Additional Paid-in Capital [Member]	Share Purchase Agreement, April 2018 [Member]Retained Earnings [Member]	Share Purchase Agreement, April 2018 [Member]Treasury Stock [Member]	Share Purchase Agreement, April 2018 [Member]	Share Purchase Agreement, December 2018 [Member]Preferred Stock [Member]	Share Purchase Agreement, December 2018 [Member]Common Stock [Member]	Share Purchase Agreement, December 2018 [Member]Additional Paid-in Capital [Member]	Share Purchase Agreement, December 2018 [Member]Retained Earnings [Member]	Share Purchase Agreement, December 2018 [Member]Treasury Stock [Member]	Share Purchase Agreement, December 2018 [Member]	Placement Agent [Member]Preferred Stock [Member]	Placement Agent [Member]Common Stock [Member]	Placement Agent [Member]Additional Paid-in Capital [Member]	Placement Agent [Member]Retained Earnings [Member]	Placement Agent [Member]Treasury Stock [Member]	Placement Agent [Member]	Warrants in Connection with Equity Consideration in Debt Issuance [Member]Preferred Stock [Member]	Warrants in Connection with Equity Consideration in Debt Issuance [Member]Common Stock [Member]	Warrants in Connection with Equity Consideration in Debt Issuance [Member]Additional Paid-in Capital [Member]	Warrants in Connection with Equity Consideration in Debt Issuance [Member]Retained Earnings [Member]	Warrants in Connection with Equity Consideration in Debt Issuance [Member]Treasury Stock [Member]	Warrants in Connection with Equity Consideration in Debt Issuance [Member]	Warrants in Connection with Equity Consideration in Payable Restructuring [Member]Preferred Stock [Member]	Warrants in Connection with Equity Consideration in Payable Restructuring [Member]Common Stock [Member]	Warrants in Connection with Equity Consideration in Payable Restructuring [Member]Additional Paid-in Capital [Member]	Warrants in Connection with Equity Consideration in Payable Restructuring [Member]Retained Earnings [Member]	Warrants in Connection with Equity Consideration in Payable Restructuring [Member]Treasury Stock [Member]	Warrants in Connection with Equity Consideration in Payable Restructuring [Member]	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Treasury Stock [Member]	Total
Balance (in shares) at Dec. 31, 2016																																												436,000
Balance at Dec. 31, 2016																																													$ 592,892,000	$ (618,668,000)	$ (3,054,000)	$ (28,830,000)
Net loss																																														(18,446,000)		(18,446,000)
Issuance of stock (in shares)	7,000							2,312,000																																				42,000
Issuance of stock			$ 10,433,000			$ 10,433,000		$ 2,000	$ 9,969,000			$ 9,971,000																																	1,030,000			1,030,000
Preferred stock conversions (in shares)																																											(4,000)	217,000
Preferred stock conversions																																													(2,000)			(2,000)
Issuance of common stock, 401(k) plan employer match (in shares)																																												7,000
Issuance of common stock, 401(k) plan employer match																																													95,000			95,000
Issuance of common stock, equity consideration in debt restructuring (in shares)																																												71,000
Issuance of common stock, equity consideration in debt restructuring																																													267,000			267,000
Exercise of prefunded common stock warrants (in shares)																																												142,000
Exercise of prefunded common stock warrants
Stock-based compensation expense																																												$ 1,000	1,561,000			1,562,000
Stock-based compensation expense																																																$ 1,600,000
Balance (in shares) at Dec. 31, 2017																																											3,000	3,227,000				3,227,421
Balance at Dec. 31, 2017																																												$ 3,000	616,245,000	(637,114,000)	$ (3,054,000)	$ (23,920,000)
Net loss																																														(4,512,000)		(4,512,000)
Stock-based compensation expense																																													418,000			418,000
Balance at Mar. 31, 2018																																												$ 3,000	616,611,000	(641,626,000)	$ (3,054,000)	$ (28,066,000)
Balance (in shares) at Dec. 31, 2017																																											3,000	3,227,000				3,227,421
Balance at Dec. 31, 2017																																												$ 3,000	616,245,000	(637,114,000)	$ (3,054,000)	$ (23,920,000)
Net loss																																																(11,491,000)
Balance at Sep. 30, 2018																																												$ 4,000	620,322,000	(648,605,000)	$ (3,054,000)	$ (31,333,000)
Balance (in shares) at Dec. 31, 2017																																											3,000	3,227,000				3,227,421
Balance at Dec. 31, 2017																																												$ 3,000	616,245,000	(637,114,000)	$ (3,054,000)	$ (23,920,000)
Net loss																																														(20,533,000)		(20,533,000)
Issuance of stock (in shares)														542,000						11,786,000						114,000
Issuance of stock														$ 1,000	$ 2,540,000			$ 2,541,000		$ 12,000	$ 41,101,000			$ 41,113,000
Preferred stock conversions (in shares)																																											(3,000)	135,000
Preferred stock conversions
Issuance of common stock, CVie Acquisition (in shares)																																												16,265,000
Issuance of common stock, CVie Acquisition																																												$ 16,000	67,484,000			67,500,000
Vesting of restricted stock units (in shares)																																												95,000
Vesting of restricted stock units
Withholding tax payments related to net share settlements of restricted stock units (in shares)																																												(31,000)
Withholding tax payments related to net share settlements of restricted stock units																																													(155,000)			(155,000)
Issuance of warrants																																	$ 417,000			$ 417,000			$ 196,000			$ 196,000
Stock-based compensation expense																																													955,000			$ 955,000
Balance (in shares) at Dec. 31, 2018																																												32,133,000				32,133,189
Balance at Dec. 31, 2018																																												$ 32,000	728,783,000	(657,647,000)	$ (3,054,000)	$ 68,114,000
Balance at Mar. 31, 2018																																												3,000	616,611,000	(641,626,000)	(3,054,000)	(28,066,000)
Net loss																																														(3,052,000)		(3,052,000)
Issuance of stock (in shares)																																												542,000
Issuance of stock																																												$ 1,000	2,593,000			2,594,000
Stock-based compensation expense																																													140,000			140,000
Balance at Jun. 30, 2018																																												4,000	619,344,000	(644,678,000)	(3,054,000)	(28,384,000)
Net loss																																														(3,927,000)		(3,927,000)
Issuance of warrants																																													833,000			833,000
Stock-based compensation expense																																													145,000			145,000
Balance at Sep. 30, 2018																																												$ 4,000	620,322,000	(648,605,000)	$ (3,054,000)	(31,333,000)
Net loss																																																$ (9,042,000)
Balance (in shares) at Dec. 31, 2018																																												32,133,000				32,133,189
Balance at Dec. 31, 2018																																												$ 32,000	728,783,000	(657,647,000)	$ (3,054,000)	$ 68,114,000
Net loss																																														(6,537,000)		(6,537,000)
Vesting of restricted stock units (in shares)																																												56,000
Vesting of restricted stock units
Withholding tax payments related to net share settlements of restricted stock units (in shares)
Withholding tax payments related to net share settlements of restricted stock units																																													(151,000)			(151,000)
Stock-based compensation expense																																													1,530,000			1,530,000
Balance at Mar. 31, 2019																																												$ 32,000	730,162,000	(664,184,000)	$ (3,054,000)	$ 62,996,000
Balance (in shares) at Dec. 31, 2018																																												32,133,000				32,133,189
Balance at Dec. 31, 2018																																												$ 32,000	728,783,000	(657,647,000)	$ (3,054,000)	$ 68,114,000
Net loss																																																$ (20,100,000)
Balance (in shares) at Sep. 30, 2019																																																32,188,855
Balance at Sep. 30, 2019																																												32,000	733,840,000	(677,747,000)	(3,054,000)	$ 53,071,000
Balance at Mar. 31, 2019																																												32,000	730,162,000	(664,184,000)	(3,054,000)	62,996,000
Net loss																																														(6,437,000)		(6,437,000)
Stock-based compensation expense																																													1,739,000			1,739,000
Balance at Jun. 30, 2019																																												32,000	731,901,000	(670,621,000)	(3,054,000)	58,270,000
Net loss																																														(7,126,000)		(7,126,000)
Stock-based compensation expense																																													1,939,000			$ 1,938,000
Balance (in shares) at Sep. 30, 2019																																																32,188,855
Balance at Sep. 30, 2019																																												$ 32,000	$ 733,840,000	$ (677,747,000)	$ (3,054,000)	$ 53,071,000

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Cash flows from operating activities:
Net loss	$ (20,533)	$ (18,446)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	160	192
Amortization of debt discount	863
Stock-based compensation	955	1,655
Amortization of prepaid interest		912
Net loss on extinguishment of debt	3,345
Gain on debt restructuring		(5,824)
Gain on sale of equipment	(9)
Changes in:
Prepaid expenses and other current assets	302	90
Accounts payable	997	2,433
Collaboration and device development payable	(510)	(343)
Accrued expenses	(276)	(2,995)
Deferred revenue - current	(686)	884
Deferred revenue - non-current	(407)	407
Other liabilities	18	(10)
Net cash used in operating activities	(15,781)	(21,045)
Cash flows from investing activities:
Cash acquired in CVie acquisition	223
Purchase of marketable securities	(13,959)
Proceeds from sale of property and equipment	9
Purchase of property and equipment		(24)
Net cash used in investing activities	(13,727)	(24)
Cash flows from financing activities:
Proceeds from Issuance of Private Placement	32,893	14,860
Proceeds from loan payable, net of expenses	6,160	3,900
Repayment of loan payable	(160)
Proceeds from convertible note payable	1,500
Repayment of convertible note payable	(1,500)
Payment for taxes related to net share settlements of restricted stock units	(155)
Proceeds from ATM Program, net of expenses		1,036
Principal payments on debt restructuring		(2,500)
Net cash provided by financing activities	38,738	17,296
Effect of exchange rates on cash	88
Net increase/(decrease) in cash, cash equivalents and restricted cash	9,318	(3,773)
Cash, cash equivalents and restricted cash - beginning of year	2,040	5,813
Cash, cash equivalents and restricted cash - end of year	11,358	2,040
Supplementary disclosure of cash flows information:
Interest paid	$ 288	$ 1,088

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Current Assets:
Cash and cash equivalents	$ 4,437,000	$ 11,187,000
Available-for-sale marketable securities		13,959,000
Prepaid expenses and other current assets	826,000	507,000
Total current assets	5,263,000	25,653,000
Property and equipment, net	877,000	802,000
Restricted cash	154,000	171,000
Operating lease right-of-use assets	1,566,000
Indefinite intangible asset	77,090,000	77,090,000
Goodwill	15,682,000	15,682,000
Total assets	100,632,000	119,398,000
Current Liabilities:
Accounts payable	607,000	3,420,000
Collaboration and device development payable, net	1,873,000	2,576,000
Accrued expenses	5,235,000	6,465,000
Operating lease liabilities - current portion	781,000
Deferred revenue - current portion		198,000
Loan payable	7,782,000	7,974,000
Total current liabilities	16,278,000	20,633,000
Operating lease liabilities - non-current portion	953,000
Restructured debt liability - contingent milestone payments	15,000,000	15,000,000
Deferred tax liabilities	15,224,000	15,476,000
Other liabilities	106,000	175,000
Total liabilities	47,561,000	51,284,000
Stockholders' Equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; 0 shares and 2,701 shares issued and outstanding at December 31, 2018 and December 31, 2017, respectively	0	0
Common stock, $0.001 par value; 120,000,000 shares authorized at December 31, 2018 and December 31, 2017; 32,133,263 and 3,227,495 shares issued at December 31, 2018 and December 31, 2017, respectively; 32,133,189 shares and 3,227,421 shares outstanding at December 31, 2018 and December 31, 2017, respectively	32,000	32,000
Additional paid-in capital	733,840,000	728,783,000
Accumulated deficit	(677,747,000)	(657,647,000)
Accumulated other comprehensive income		0
Treasury stock (at cost); 74 shares	(3,054,000)	(3,054,000)
Total stockholders' equity	53,071,000	68,114,000
Total liabilities & stockholders' equity	$ 100,632,000	$ 119,398,000

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Sep. 30, 2019	Dec. 31, 2018	Dec. 31, 2017	Feb. 15, 2017
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0	2,701
Preferred stock, shares outstanding (in shares)	0	0	2,701
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	120,000,000	120,000,000	120,000,000
Common stock, shares issued (in shares)	32,188,929	32,133,263	3,227,495
Common stock, shares outstanding (in shares)	32,188,855	32,133,189	3,227,421
Treasury stock, shares (in shares)	74	74	74

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended											9 Months Ended		12 Months Ended
	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
Revenues:
Total revenues				$ 304	$ 229	$ 1,051	$ 204	$ 102	$ 17	$ 1,147	$ 219	$ 198	$ 1,484	$ 1,788	$ 1,485
Expenses:
Research and development	3,792			2,368	2,197	2,879	3,118	2,418	3,062	5,483	6,413	10,547	8,194	10,562	17,376
General and administrative	3,395			2,787	1,500	1,208	1,926	1,182	1,749	1,804	1,922	9,990	4,634	7,421	6,657
Total operating expenses	7,187			5,155	3,697	4,087	5,044	3,600	4,811	7,287	8,335	20,537	12,828	17,983	24,033
Operating loss	(7,187)			(4,851)	(3,468)	(3,036)	(4,840)	(3,498)	(4,794)	(6,140)	(8,116)	(20,339)	(11,344)	(16,195)	(22,548)
Other income / (expense):
Interest income	25				1							124	9	15	12
Interest expense	(105)				(460)							(358)	(642)	(1,409)	(1,863)
Other income, net	141											473	486	401	129
Other income / (expense), net	61				(459)							239	(147)	(4,338)	4,102
Net loss	$ (7,126)	$ (6,437)	$ (6,537)	(9,042)	$ (3,927)	(3,052)	(4,512)	2,473	(5,443)	(6,752)	(8,724)	$ (20,100)	$ (11,491)	$ (20,533)	$ (18,446)
Net loss per common share
Basic and diluted (in dollars per share)	$ (0.22)				$ (1.04)							$ (0.62)	$ (3.21)	$ (7.74)	$ (24.14)
Weighted average number of common shares outstanding
Basic and diluted (in shares)	32,189,000				3,769,000							32,173,000	3,585,000	4,493	1,028
Grant [Member]
Revenues:
License revenue with affiliate					$ 70								$ 765	$ 765	$ 1,383
License [Member]
Revenues:
License revenue with affiliate				$ 304	$ 159	$ 356	$ 204	$ 102				$ 198	$ 719	$ 1,023	$ 102

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Net loss	$ (7,126)	$ (3,927)	$ (20,100)	$ (11,491)
Other comprehensive income:
Unrealized gain (loss) on marketable securities	(12)
Comprehensive loss	$ (7,138)	$ (3,927)	$ (20,100)	$ (11,491)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($) shares in Thousands	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Treasury Stock [Member]	Total
Balance at Dec. 31, 2016			$ 592,892,000	$ (618,668,000)		$ (3,054,000)	$ (28,830,000)
Net loss				(18,446,000)			(18,446,000)
Stock-based compensation expense							1,600,000
Issuance of stock (in shares)		42
Issuance of stock			1,030,000				1,030,000
Balance (in shares) at Dec. 31, 2017	3	3,227
Balance at Dec. 31, 2017		$ 3,000	616,245,000	(637,114,000)		$ (3,054,000)	(23,920,000)
Net loss				(4,512,000)			(4,512,000)
Share Purchase Agreement, April 2018			(52,000)				(52,000)
Stock-based compensation expense			418,000				418,000
Balance (in shares) at Mar. 31, 2018	3	3,227
Balance at Mar. 31, 2018		$ 3,000	616,611,000	(641,626,000)		$ (3,054,000)	(28,066,000)
Balance (in shares) at Dec. 31, 2017	3	3,227
Balance at Dec. 31, 2017		$ 3,000	616,245,000	(637,114,000)		$ (3,054,000)	(23,920,000)
Net loss							(11,491,000)
Unrealized gain (loss) on marketable securities
Balance (in shares) at Sep. 30, 2018	3	3,769
Balance at Sep. 30, 2018		$ 4,000	620,322,000	(648,605,000)		$ (3,054,000)	(31,333,000)
Balance (in shares) at Dec. 31, 2017	3	3,227
Balance at Dec. 31, 2017		$ 3,000	616,245,000	(637,114,000)		$ (3,054,000)	(23,920,000)
Net loss				(20,533,000)			(20,533,000)
Stock-based compensation expense			955,000				955,000
Vesting of restricted stock units (in shares)		95
Vesting of restricted stock units
Withholding tax payments related to net share settlements of restricted stock units (in shares)		(31)
Withholding tax payments related to net share settlements of restricted stock units			(155,000)				(155,000)
Balance (in shares) at Dec. 31, 2018		32,133
Balance at Dec. 31, 2018		$ 32,000	728,783,000	(657,647,000)		$ (3,054,000)	68,114,000
Balance (in shares) at Mar. 31, 2018	3	3,227
Balance at Mar. 31, 2018		$ 3,000	616,611,000	(641,626,000)		$ (3,054,000)	(28,066,000)
Net loss				(3,052,000)			(3,052,000)
Stock-based compensation expense			140,000				140,000
Issuance of stock (in shares)		542
Issuance of stock		$ 1,000	2,593,000				2,594,000
Balance (in shares) at Jun. 30, 2018	3	3,769
Balance at Jun. 30, 2018		$ 4,000	619,344,000	(644,678,000)		$ (3,054,000)	(28,384,000)
Net loss				(3,927,000)			(3,927,000)
Stock-based compensation expense			145,000				145,000
Issuance of warrants			833,000				833,000
Unrealized gain (loss) on marketable securities
Balance (in shares) at Sep. 30, 2018	3	3,769
Balance at Sep. 30, 2018		$ 4,000	620,322,000	(648,605,000)		$ (3,054,000)	(31,333,000)
Net loss							(9,042,000)
Balance (in shares) at Dec. 31, 2018		32,133
Balance at Dec. 31, 2018		$ 32,000	728,783,000	(657,647,000)		$ (3,054,000)	68,114,000
Net loss				(6,537,000)			(6,537,000)
Stock-based compensation expense			1,530,000				1,530,000
Vesting of restricted stock units (in shares)		56
Vesting of restricted stock units
Withholding tax payments related to net share settlements of restricted stock units (in shares)
Withholding tax payments related to net share settlements of restricted stock units			(151,000)				(151,000)
Unrealized gain (loss) on marketable securities					40,000		40,000
Balance (in shares) at Mar. 31, 2019		32,189
Balance at Mar. 31, 2019		$ 32,000	730,162,000	(664,184,000)	40,000	$ (3,054,000)	62,996,000
Balance (in shares) at Dec. 31, 2018		32,133
Balance at Dec. 31, 2018		$ 32,000	728,783,000	(657,647,000)		$ (3,054,000)	68,114,000
Net loss							(20,100,000)
Unrealized gain (loss) on marketable securities
Balance (in shares) at Sep. 30, 2019		32,189
Balance at Sep. 30, 2019		$ 32,000	733,840,000	(677,747,000)		$ (3,054,000)	53,071,000
Balance (in shares) at Mar. 31, 2019		32,189
Balance at Mar. 31, 2019		$ 32,000	730,162,000	(664,184,000)	40,000	$ (3,054,000)	62,996,000
Net loss				(6,437,000)			(6,437,000)
Stock-based compensation expense			1,739,000				1,739,000
Unrealized gain (loss) on marketable securities					(28,000)		(28,000)
Balance (in shares) at Jun. 30, 2019		32,189
Balance at Jun. 30, 2019		$ 32,000	731,901,000	(670,621,000)	12,000	$ (3,054,000)	58,270,000
Net loss				(7,126,000)			(7,126,000)
Stock-based compensation expense			1,939,000				1,938,000
Unrealized gain (loss) on marketable securities					(12,000)		(12,000)
Balance (in shares) at Sep. 30, 2019		32,189
Balance at Sep. 30, 2019		$ 32,000	$ 733,840,000	$ (677,747,000)		$ (3,054,000)	$ 53,071,000

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Cash flows from operating activities:
Net loss	$ (20,100)	$ (11,491)
Adjustments to reconcile net loss to net cash used in operating activities:
Recognition of deferred revenue	(198)	(789)
Depreciation	178	121
Amortization of operating lease right-of-use assets	741
Amortization of debt discount	127	303
Stock-based compensation	5,208	703
Realized gain on investments	(75)
Gain on sale of equipment		(9)
Changes in:
Prepaid expenses and other current assets	389	23
Accounts payable	(2,813)	1,471
Collaboration and device development payable	(830)	146
Accrued expenses	(1,166)	(68)
Operating lease liabilities	(784)
Other liabilities	119
Net cash used in operating activities	(19,204)	(9,590)
Cash flows from investing activities:
Proceeds from sale of marketable securities	13,988
Purchase of property and equipment	(129)
Proceeds from sale of property and equipment		9
Net cash used in investing activities	13,859	9
Cash flows from financing activities:
Proceeds from loan payable, net of expenses		4,280
Proceeds from private placement issuance of securities, net of expenses		2,541
Proceeds from convertible note payable		1,500
Repayment of loan payable	(820)
Payment for taxes related to net share settlements of restricted stock units	(151)
Net cash provided by financing activities	(971)	8,321
Effect of exchange rate changes on cash and cash equivalents	(451)
Net decrease in cash and cash equivalents	(6,767)	(1,260)
Cash, cash equivalents and restricted cash - beginning of year	11,358	2,040
Cash, cash equivalents and restricted cash - end of year	4,591	780
Supplementary disclosure of non-cash activity:
Prepayment of director and officer insurance through 3rd party financing	$ 708

Note 1 - The Company and Descri

Note 1 - The Company and Description of Business	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	Note 1 The Company and Description of Business Windtree Therapeutics, Inc. (referred to as “we,” “us,” or the “Company”) is a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases. Through 2018, KL4 December 2018, may Our four 1 2 KL4 3 KL4 4 2 3. 2a See 3 The reader is referred to, and encouraged to read in its entirety, Item 1 10 December 31, 2018 April 16, 2019, 10 April 23, 2019 ( 2018 10 10	Note 1 The Company and Description of Business Windtree Therapeutics, Inc. (referred to as “we,” “us,” or the “Company”) is a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute pulmonary and cardiovascular diseases. Historically, our focus has been on the development of our proprietary KL4 December 2018 ( see 3 Our four 1 2 KL4 3 KL4 4 Heart failure is a chronic, progressive disease resulting from structural or functional cardiac abnormalities and is characterized by inadequate pumping function of the heart that results in fluid accumulation manifesting as pulmonary congestion, peripheral edema and congestion in other parts of the body. Insufficient cardiac output can result in inadequate peripheral perfusion that increases the risk of other organ dysfunction such as renal failure. Heart failure commonly but episodically worsens to a point of decompensation, a condition called ADHF. We are developing istaroxime for the treatment of ADHF. Istaroxime has a dual mechanism of action referred to as luso-inotropic, that may two 2 may 2019, AEROSURF (lucinactant for inhalation) is an investigational combination drug/device product that we are developing to improve the management of RDS in premature infants who may not may may KL4 2017, 2b not 72 24% 50 2 50 2019, 3 not 2b KL4 We are also assessing potential development pathways to secure marketing approval for lyophilized KL4 KL4 KL4 2012 second 2019. may not We also believe that our lyophilized KL4 may Our fourth 20% 25% may may may three 2b two one one no 2019, The reader is referred to, and encouraged to read in its entirety, “Item 1 10

Note 2 - Basis of Presentation

Note 2 - Basis of Presentation	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Notes to Financial Statements
Basis of Accounting [Text Block]	Note 2 Basis of Presentation These interim unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the US (US GAAP) for interim financial information in accordance with the instructions to Form 10 not three nine September 30, 2019 not may December 31, 2019. no December 31, 2018. December 31, 2018 2018 10 10	Note 2 Basis of Presentation The consolidated financial statements are prepared in accordance with accounting principles generally accepted in the US (US GAAP) and include accounts of Windtree and its wholly-owned subsidiaries. Intercompany balances and transactions have been eliminated in consolidation. In the opinion of management, all adjustments (consisting of normally recurring accruals) considered for fair presentation have been included. When necessary, prior year’s consolidated financial statements have been reclassified to conform to the current year presentation.

Note 3 - Business Combination

Note 3 - Business Combination	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Business Combination Disclosure [Text Block]	Note 3 Business Combination On December 21, 2018 ( 16,256,060 $67.5 In connection with the CVie Acquisition, our board of directors declared a dividend to the holders of record of outstanding shares of common stock, and holders of certain warrants to purchase common stock, that were outstanding on December 20, 2018 0.6148 2,963,167 five one first 3 815, $12.5 two first 3 two three Significant Input Assumptions of Warrant Valuation Historical volatility 116 % Expected term (in years) 2.5 Risk-free interest rate 2.62 % On the Acquisition Date, we entered into an indemnification letter agreement (the Indemnification Letter Agreement) with Lee’s Pharmaceutical Holdings Limited (Lee’s), pursuant to which Lee’s agreed to indemnify the holders of issued and outstanding shares of common stock on December 20, 2018 ( not 984,000 one The aggregate purchase price has been allocated based on the fair value of assets acquired and liabilities assumed as of the acquisition date. The excess of the $67.5 not (in thousands) Cash and cash equivalents $ 193 Restricted cash 31 Prepaid expenses and other current assets 387 Property and equipment, net 76 Intangible assets 77,090 Total identifiable assets acquired $ 77,777 Current liabilities $ (2,590 ) Loan payable, current (3,453 ) Loan payable, non current (4,491 ) Deferred tax liabilities, noncurrent (15,418 ) Other liabilities, noncurrent (7 ) Net identifiable assets acquired 51,818 Goodwill 15,682 Net assets acquired $ 67,500 The acquired identifiable intangible assets consist of in-process research and development (“IPR&D”) of approximately $77.1 See, 5 From the Acquisition Date to December 31, 2018, $0.5 The following table presents unaudited consolidated pro forma results of operations based on our historical financial statements and adjusted for the acquisition of CVie as if it occurred on January 1, 2017. not Year Ended December 31, (in thousands, except per share data) 2018 2017 Pro forma net loss attributable to common shareholders $ (38,082 ) $ (34,616 ) Pro forma EPS - basic and diluted $ (1.20 ) $ (1.19 ) For the year ended December 31, 2018, December 31, 2018 2017,

Note 4 - Liquidity Risks and Ma

Note 4 - Liquidity Risks and Management's Plans	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Notes to Financial Statements
Liquidity Disclosures [Text Block]	Note 3 Liquidity Risks and Management’s Plans As of September 30, 2019, $4.4 $16.3 $7.8 see 7 October 24, 2019, $1.0 November 2019 We have an immediate need for additional capital to continue our operations. Even if we are able to secure such additional capital in the near term, we expect to continue to incur significant losses and will require significant additional capital to support our operations, advance our clinical development programs, and satisfy existing obligations. We currently only have cash and cash equivalent resources to fund our business operations through late- November 2019, not one To alleviate the conditions that raise substantial doubt about our ability to continue as a going concern, management plans, and is currently actively engaged in discussions with various parties, including our largest shareholders, seeking to secure additional capital, potentially through one none no may not none November 2019 not one The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business, and do not As of September 30, 2019, 120.0 5.0 72.0 5.0 not	Note 4 Liquidity Risks and Management’s Plans As of December 31, 2018, $11.2 $14.0 $20.6 $8.0 see 11 April 5, 2019, October 2019. Although we believe that the December 2018 $39 may October 2019, not one To alleviate the conditions that raise substantial doubt about our ability to continue as a going concern, management plans to raise additional capital through a combination of public or private equity offerings and strategic transactions, including but not none no none not one The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business, and do not As of December 31, 2018, 120 5 72.0 5.0 not

Note 5 - Accounting Policies an

Note 5 - Accounting Policies and Recent Accounting Pronouncements	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Notes to Financial Statements
Significant Accounting Policies [Text Block]	Note 4 Summary of Significant Accounting Policies Principles of C onsolidation The condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the US (US GAAP) and include accounts of Windtree Therapeutics, Inc. and its wholly-owned subsidiaries, CVie Investments, CVie Therapeutics, and a presently inactive subsidiary, Discovery Laboratories, Inc. Business C ombinations We follow the acquisition method for an acquisition of a business where the purchase price is allocated to the assets acquired and liabilities assumed based on their estimated fair values at the dates of acquisition. The excess of the fair value of purchase consideration over the fair value of the assets acquired and liabilities assumed is recorded as goodwill. Such valuations require management to make significant estimates and assumptions, especially with respect to intangible assets. Management’s estimate of fair value is based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and as such, actual results may Goodwill and I ntangible A ssets We record acquired identified intangibles, which includes intangible assets (such as goodwill and other intangibles), based on estimated fair value. The acquired in-process research and development (IPR&D) assets are considered indefinite-lived intangible assets until completion or abandonment of the associated research and development efforts. IPR&D is not may September 30, 2019 December 31, 2018: (in thousands) Carrying Value Istaroxime drug candidate $ 22,340 Rostafuroxin drug candidate 54,750 Total $ 77,090 Goodwill represents the excess of the purchase price over the fair value of assets acquired and liabilities assumed in a business combination and is not may not not Foreign C urrency T ransactions The functional currency for our foreign subsidiaries is US dollars. We remeasure monetary assets and liabilities that are not $0.1 $0.4 three nine September 30, 2019. no three nine September 30, 2018. Use of E stimates The preparation of financial statements, in conformity with US GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Marketable S ecurities Marketable securities consist of investments in US Treasury securities. Management determines the appropriate classification of these securities at the time they are acquired and evaluates the appropriateness of such classifications at each balance sheet date. We classify investments as available-for-sale pursuant to Financial Accounting Standards Board (FASB) Accounting Standard Codification (ASC) 320, three September 30, 2019, $14,000 $12,000 nine September 30, 2019, $75,000 no three nine September 30, 2018. We review investments for other-than-temporary impairment whenever the fair value of an investment is less than the amortized cost and evidence indicates that an investment’s carrying amount is not not Available-for-sale marketable securities are classified as marketable securities, current or marketable securities, non-current depending on the contractual maturity date of the individual available-for-sale security. Leases Effective January 1, 2019, 842, Leases 842 not 840, Leases At the inception of an arrangement, we determine whether an arrangement is, or contains, a lease based on the unique facts and circumstances present in the arrangement. An arrangement is, or contains, a lease if the arrangement conveys the right to control the use of an identified asset for a period of time in exchange for consideration. Leases with a term greater than one not 12 not Operating lease liabilities and their corresponding operating lease right-of-use assets are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may not 842, Restructured D ebt L iability – Co ntingent M ilestone P ayment In conjunction with the November 2017 s ee, 8 $15 October 27, 2017 ( not Research and D evelopment We account for research and development expense by the following categories: (a) product development and manufacturing, (b) clinical medical and regulatory operations, and (c) direct preclinical and clinical development programs. Research and development expense includes personnel, facilities, manufacturing and quality operations, pharmaceutical and device development, research, clinical, regulatory, other preclinical and clinical activities and medical affairs. Research and development costs are charged to operations as incurred in accordance with ASC Topic 730, Research and Development Net L oss per C ommon S hare Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding for the period. Diluted net loss per common share is computed by giving effect to all potentially dilutive securities outstanding for the period. As of September 30, 2019 2018, 15.6 1.3 three nine September 30, 2019 2018, Income T axes We account for income taxes in accordance with ASC Topic 740, Accounting for Income Taxes We use a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Because we have never realized a profit, management has fully reserved the net deferred tax asset since realization is not Recently A dopted A ccounting S tandards In February 2016, No. 2016 02, Leases 2016 02 2016 02 842 840, Leases 842 2018. January 1, 2019 not not January 1, 2019. 840 ASC 842 not 12 not The adoption of this standard resulted in the recognition of operating lease liabilities and related right-of-use assets on our condensed consolidated balance sheets of $2.2 $2.0 842 $72,000 $139,000 not 10 In January 2017, No. 2017 04, 350 second December 15, 2019 January 1, 2019 December 31, 2019. Recently Issued Accounting Standards In August 2018, No. 2018 13, 820 2018 13 820. no 1 2 3 3 3 2018 13 December 15, 2019. 2018 13	Note 5 Accounting Policies and Recent Accounting Pronouncements Principles of consolidation The consolidated financial statements are prepared in accordance with accounting principles generally accepted in the US (US GAAP) and include accounts of Windtree Therapeutics, Inc. and its wholly-owned subsidiaries, CVie Investments Limited and its wholly-owned subsidiary, CVie Therapeutics Limited; and a presently inactive subsidiary, Discovery Laboratories, Inc. (formerly known as Acute Therapeutics, Inc.). Business c ombinations We follow the acquisition method for an acquisition of a business where the purchase price is allocated to the assets acquired and liabilities assumed based on their estimated fair values at the dates of acquisition. The excess of the fair value of purchase consideration over the fair value the assets acquired and liabilities assumed is recorded as goodwill. Such valuations require management to make significant estimates and assumptions, especially with respect to intangible assets. Management’s estimate of fair value is based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and as such, actual results may Goodwill and i ntangible a ssets We record acquired identified intangibles, which includes intangible assets (such as goodwill and other intangibles), based on estimated fair value. The acquired in-process research and development (“IPR&D”) assets are considered indefinite-lived intangible assets until completion or abandonment of the associated research and development efforts. IPR&D is not may December 31, 2018: (in thousands) Estimated Fair Value Istaroxime drug candidate $ 22,340 Rostafuroxin drug candidate 54,750 Total $ 77,090 Goodwill represents the excess of the purchase price over the fair value assets acquired and liabilities assumed in a business combination and is not may not not Foreign c urrenc y transactions The functional currency for our foreign subsidiaries is US Dollars. We remeasure monetary assets and liabilities that are not $0.1 December 31, 2018. no December 31, 2017. Use of estimates The preparation of financial statements, in conformity with accounting principles generally accepted in the U. S., requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Cash and cash equivalents Cash and cash equivalents are held in at domestic and foreign financial institutions and consist of liquid investments and money market funds with a maturity from date of purchase of 90 Marketable securities Marketable securities consist of investments in US Treasury securities. Management determines the appropriate classification of these securities at the time they are acquired and evaluates the appropriateness of such classifications at each balance sheet date. We classify investments as available-for-sale pursuant to Financial Accounting Standards Board (“FASB”) Accounting Standard Codification (“ASC”) 320, no December 31, 2018 2017. no December 31, 2018 2017. We review investments for other-than-temporary impairment whenever the fair value of an investment is less than the amortized cost and evidence indicates that an investment’s carrying amount is not not Available-for-sale marketable securities are classified as marketable securities, current or marketable securities, non-current depending on the contractual maturity date of the individual available-for-sale security. Fair value of financial instruments Our financial instruments consist principally of cash and cash equivalents and restricted cash. The fair values of our cash equivalents are based on quoted market prices. The carrying amount of cash equivalents is equal to their respective fair values at December 31, 2018 2017, Property and equipment Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets (generally three ten Restricted cash Restricted cash consists principally of a $140,000 May 26, 2004 $31,000 see, 18 Long-lived assets Our long-lived assets, primarily consisting of intangible assets, are reviewed for impairment when events or changes in circumstances indicate the carrying amount of an asset may not No December 31, 2018 2017 no not Collaborative arrangements We account for collaborative arrangements in accordance with applicable accounting guidance provided in ASC Topic 808, Collaborative Arrangements See, 16 Restructured debt liability – contingent milestone payment In conjunction with the November 2017 see, 13 $15 October 27, 2017 ( not Deferred revenue Deferred revenue represents amounts received prior to satisfying the revenue recognition criteria ( see 12 not 12 Deferred revenue primarily consists of amounts related to an upfront license fee received in July 2017 see 16 Revenue recognition Effective January 1, 2018, 606, 606, In accordance with ASC Topic 606, 606, five (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. We only apply the five 606, We have concluded that our government grants are not 606 not 958 605, Not not In the absence of applicable guidance under US GAAP, effective January 1, 2018, We believe this policy is consistent with the overarching premise in ASC Topic 606, no 606. 606. Prior to January 1, 2018, not no Research and development We account for research and development expense by the following categories: (a) product development and manufacturing, (b) medical and regulatory operations, and (c) direct preclinical and clinical development programs. Research and development expense includes personnel, facilities, manufacturing and quality operations, pharmaceutical and device development, research, clinical, regulatory, other preclinical and clinical activities and medical affairs. Research and development costs are charged to operations as incurred in accordance with Accounting Standards Codification (ASC) Topic 730, Research and Development Stock-based compensation Stock-based compensation is accounted for under the fair value recognition provisions of ASC Topic 718, Stock Compensation 718 See 15 Warrant accounting We account for common stock warrants in accordance with applicable accounting guidance provided in ASC Topic 815, Derivatives and Hedging – Contracts in Entity’s Own Equity 815 Income taxes We account for income taxes in accordance with ASC Topic 740, We use a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Because we have never realized a profit, management has fully reserved the net deferred tax asset since realization is not Beneficial Conversion Feature A beneficial conversion feature arises when a debt or equity security is issued with an embedded conversion option that is beneficial to the investor (or in the money) at inception due to the conversion option having an effective conversion price that is less than the fair value of the underlying stock at the commitment date. Preferred Stock The issuance of Series A Convertible Preferred Stock (Preferred Shares) in the first 2017 14 $3.6 one first 2017. An additional discount to the Preferred Shares of $4.5 December 31, 2018 December 31, 2017, $1.7 $2.8 December 31, 2018, no Convertible Note The issuance on July 2, 2018 $1.5 $1.5 $0.4 $0.4 $1.5 see 11 December 27, 2018, $1.5 $0.4 $5.11 $4.00, 375,000 Net loss per common share Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding for the period. Diluted net loss per common share is computed by giving effect to all potentially dilutive securities outstanding for the period. For the years ended December 31, 2018 2017, 14.4 1.0 December 31, 2018 2017, We do not Concentration of Suppliers We currently obtain the active pharmaceutical ingredients (APIs) of our KL4 third KL4 one Business segments We currently operate in one one not Recent Accounting Pronouncements Recently Adopted Accounting Standards In May 2014, 2014 09, Revenue from Contracts with Customers (Topic 606 606 2014 09, January 1, 2018 June 2017, 2014 09 no no See, 16 In May 2017, 2017 09, Compensation—Stock Compensation (Topic 718 December 31, 2018 2017 09 January 1, 2018 not 2018 In August 2016, 2016 15, Statement of Cash Flows (Topic 230 eight one December 31, 2018 2016 15 January 1, 2018 not 2018 In January 2017, 2017 01, Business Combinations (Topic 805 first not not December 31, 2018 2017 01 January 1, 2018 not 2018 Recent Accounting Pronouncements In February 2016, 2016 02, Leases 842 January 1, 2019. not In January 2017, 2017 04, Intangibles - Goodwill and Other: Simplifying the Test for Goodwill Impairment 2017 04 second two not 2017 04 December 15, 2019; 2017 04 not

Note 6 - License Revenue with A

Note 6 - License Revenue with Affiliate	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	Note 5 License Revenue with Affiliate Three Months Ended Nine Months Ended (in thousands) 2019 2018 2019 2018 License revenue with affiliate $ - $ 159 $ 198 $ 719 License revenue with affiliate represents revenue from a License Agreement with Lee’s Pharmaceutical (HK) Ltd. (Lee’s (HK)), an affiliate of our largest shareholder, Lee’s Pharmaceutical Holdings Limited (Lee’s), and constitutes a contract with a customer accounted for in accordance with ASC Topic 606. June 30, 2019, no	Note 6 License Revenue with Affiliate Year Ended December 31, (in thousands) 2018 2017 License revenue with affiliate $ 1,023 $ 102 License revenue with affiliate for years ended December 31, 2018 2017 606, January 1, 2018 ( see 5 16 no 606.

Note 7 - Fair Value Measurement

Note 7 - Fair Value Measurements	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Notes to Financial Statements
Fair Value Disclosures [Text Block]	Note 6 Fair Value of Financial Instruments Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on three first two ● Level 1 ● Level 2 1 not ● Level 3 no Fair Value on a Recurring Basis The tables below categorize assets and liabilities measured at fair value on a recurring basis for the periods presented: Fair Value Fair value measurement using September 30, (in thousands) 2019 Level 1 Level 2 Level 3 Assets: Cash and cash equivalents $ 4,437 $ 4,437 $ - $ - U.S. Treasury notes - - - - Certificate of deposit 154 154 - - Total Assets $ 4,591 $ 4,591 $ - $ - Fair Value Fair value measurement using December 31, (in thousands) 2018 Level 1 Level 2 Level 3 Assets: Cash and cash equivalents $ 5,234 $ 5,234 $ - $ - U.S. Treasury notes 19,912 19,912 - - Certificate of deposit 171 171 - - Total Assets $ 25,317 $ 25,317 $ - $ -	Note 7 Fair Value Measurements Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on three first two ● Level 1 ● Level 2 1 not ● Level 3 no Fair Value on a Recurring Basis Assets and liabilities measured at fair value on a recurring basis are categorized in the table below as of December 31, 2018 2017: Fair Value Fair value measurement using December 31, (in thousands) 2018 Level 1 Level 2 Level 3 Assets: Cash and cash equivalents $ 5,234 $ 5,234 $ - $ - U.S. Treasury notes 19,912 $ 19,912 Certificate of deposit 171 171 - - Total Assets $ 25,317 $ 25,317 $ - $ - Fair Value Fair value measurement using December 31, (in thousands) 2017 Level 1 Level 2 Level 3 Assets: Cash and cash equivalents $ 1,815 $ 1,815 $ - $ - Certificate of deposit 225 225 - - Total Assets $ 2,040 $ 2,040 $ - $ -

Note 8 - Property and Equipment

Note 8 - Property and Equipment	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	Note 8 Property and Equipment Property and equipment is comprised of the following: December 31, (in thousands) 2018 2017 Manufacturing, laboratory & office equipment $ 4,359 $ 4,965 Furniture & fixtures 390 615 Leasehold improvements 2,469 2,458 Subtotal 7,218 8,038 Accumulated depreciation and amortization (6,416 ) (7,153 ) Property and equipment, net $ 802 $ 885 Depreciation expense on property and equipment for the years ended December 31, 2018 2017 $0.2 $0.2

Note 9 - Collaboration and Devi

Note 9 - Collaboration and Device Development Payable	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	Note 9 Collaboration and Device Development Payable Collaboration and device development payable represents amounts due to Battelle under a collaboration agreement related to the development of our phase 3 see 16 June 2012 2 December 31, 2018 2017, $2.6 $4.4 Restructuring of the Battelle Payables On December 7, 2018, 6.0% $3.0 30 December 2018 $1.0 see 14 $972,281, $1,250,000, five $250,000, $25.0 $35.0 two first one 3 December 31, 2019, January 7, 2020. Management determined the payment restructuring agreement of the Battelle Payables do not not not In connection with the payment restructuring agreement, we also issued to Battelle Series E Warrants (“Series E Warrants”) to purchase 75,000 $6.50 may 5 December 11, 2023. may not 9.99% The Series E Warrants are derivatives that qualify for an exemption from liability accounting as provided for in ASC Topic 815, five Significant Input Assumptions of Warrant Valuation Historical volatility 103 % Expected term (in years) 5 Risk-free interest rate 2.70 % As of December 31, 2018, $0.3 Extinguishment of Collaboration and Device Development Payable On December 21, 2018, $1.0 301,823 $3.3132 51,310 $3.68 99,602 $4.05 18th may 5 The conversion of the Battelle Payables is treated as an extinguishment of outstanding liabilities. We recorded a loss on extinguishment of debt of approximately $0.5 $1.5 December 21, 2018 $1.0

Note 10 - Accrued Expenses

Note 10 - Accrued Expenses	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]	Note 10 Accrued Expenses Accrued expenses are comprised of the following: December 31, (in thousands) 2018 2017 Professional fees $ 2,473 $ 412 Research and development 2,361 1,778 Salaries, bonus & benefits 815 1,008 Manufacturing operations 212 537 Other 604 399 Total accrued expenses $ 6,465 $ 4,134

Note 11 - Loan Payable

Note 11 - Loan Payable	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Notes to Financial Statements
Short-term Debt [Text Block]	Note 7 Loan s Payable In January 2018 March 2018, $1.5 $1.0 one 6% December 31, 2018. March 1, 2018 ( December 5, 2018, $6.0 $1.5 $1.0 Assumption of bank debt as part of the CVie Acquisition As part of the CVie Acquisition, we assumed approximately $4.5 March 2020. In September 2016, 12 $2.9 $5.8 September 2017. 110% not 90 0.91%. September 11, 2019 six March 11, 2020. 2021. As of September 30, 2019, $4.5 Assumption of Lee's debt as part of the CVie Acquisition As part of the CVie Acquisition, we assumed approximately $3.5 From April 24, 2018 November 16, 2018, four $3.5 4% one $0.5 April 2019; $0.3 September 2019; $0.2 October 2019; $2.5 November 2019. no April 30, 2021. During the quarter ended March 31, 2019, $0.45 April 2018 $50,000 April 2019. September 30, 2019, $3.0 Loan payable to Bank Direct Capital Finance In May 2019, $0.7 5.35% $80,000 March 2020. September 30, 2019, $0.4	Note 11 – Loan Payable In January 2018 March 2018, $1.5 $1.0 one 6% December 31, 2018. March 1, 2018 ( During the third fourth 2018, August 14, 2018 $0.3 August 29, 2018, $0.48 September 12, 2018 $0.5 September 27, 2018 $0.5 October 19, 2018 $0.43 November 2, 2018 $0.5 November 19, 2018 $0.35 December 5, 2018 $0.6 6% $30 March 31, 2019. Extinguishment of Loan Payable On December 21, 2018, $6.0 1,810,938 $3.3132 307,859 $3.68 597,610 $4.05 18 may 5 The conversion of the loan payable to LPH is treated as an extinguishment of debt and does not third $3.2 $9.2 December 21, 2018, $6.0 The balance of the loan payable to LPH of $160,000 $182,000 December 27, 2018. Assumption of bank debt as part of the CVie Acquisition As part of the CVie Acquisition, we assumed approximately $4.5 $138.0 March 2020. In September 2016, 12 $2.9 $90.0 $5.84 $180.0 September 2017. 110% not 90 0.91%. September 11, 2019 six March 11, 2020. not $4.5 As of December 31, 2018, $4.5 $138.0 Assumption of Lee’s debt as part of the CVie Acquisition As part of the CVie Acquisition, we assumed approximately $3.5 $106.2 From April 24, 2018 November 16, 2018, four $3.5 4% four one $0.5 April 2019; $0.3 September 2019; $0.2 October 2019; $2.5 November 2019. As of December 31, 2018, $3.5 $106.2

Note 12 - Convertible Note Paya

Note 12 - Convertible Note Payable	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Convertible Note Payable Disclosure [Text Block]	Note 12 Convertible Note Payable On July 2, 2018, $1.5 two $1.0 $0.5 July 23, 2018. December 31, 2018 15% $4.00. In connection with the Note, we issued to Panacea warrants (the “Series D Warrants”) to purchase 187,500 $4.00 may six fifth may not 9.99% may sixty-one We recorded the Note as current debt at its face value of $1.5 $0.4 $0.4 $1.5 815, Derivatives and Hedging – Contracts in Entity’s Own Equity The fair value at issuance of the Panacea Warrants was determined using the Black-Scholes option-pricing model. The input assumptions used in the valuation are the historical volatility of our common stock price, the expected term of the warrants, and the risk-free interest rate based on the five Significant Input Assumptions of Warrant Valuation Historical volatility 103 % Expected term (in years) 5 Risk-free interest rate 2.75 % The following amounts comprise the convertible note interest expense for the periods presented: Year Ended (in thousands) 2018 Non-cash amortization of debt discounts $ 833 Cash interest expense 106 Total convertible note interest expense $ 939 Extinguishment of Panacea Convertible Promissory Note On December 27, 2018, $1.5 $0.4 $5.11 $4.00, 375,000

Note 13 - Restructured Debt Lia

Note 13 - Restructured Debt Liability	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Notes to Financial Statements
Long-term Debt [Text Block]	Note 8 Restructured Debt Liability September 30, December 31, (in thousands) 2019 2018 Restructured debt liability - contingent milestone payments $ 15,000 $ 15,000 On November 1, 2017, $25 25,000 $786.80 $2.5 71,111 2% $15 $15 see 4 not	Note 13 Restructured Debt Liability December 31, December 31, (in thousands) 2018 2017 Restructured debt liability - contingent milestone payments $ 15,000 $ 15,000 On November 1, 2017, $25 25,000 $786.80 $2.5 71,111 2% $15 $15 see 5 not

Note 14 - Stockholders' Equity

Note 14 - Stockholders' Equity	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	Note 14 Stockholders’ Equity Private Placement Offerings December 2018 Financing On December 21, 2018, 11,785,540 $3.3132, $39.0 $6.0 $1.0 2,003,541 $3.68 18 3,889,229 $4.05 5 December 2018 December 2018 may not 9.99% December 2018 Under the Registration Rights Agreement, we agreed to file by May 1, 2019 December 2018 April 2018 On April 4, 2018, $2.6 $4.80, 541,667 135,417 $5.52 6 seventh 25% 180th March 30, 2018, may Share Purchase Agreement Effective October 27, 2017, $10 2,311,604 $4.326 15% 10 73% $3.9 August 14, 2017, two 30th no 24 2011 2017 2018 two March 15, 2018 March 15, 2019. Contemporaneously with the execution of the SPA, we and LPH entered into a registration rights agreement pursuant to which we agreed to provide certain registration rights with respect to the Shares under the SPA, which rights are limited to registration of up to 25% 18 506 4 2 1933. February 2017 On February 15, 2017, 7,049 $1,495, $10.5 $1.6 December 31, 2016 first second 2017. one $0.001 1 50 $27.40 50 1 may February 15, 2024. 1 may not 9.99% three February 13, 2018, To facilitate consummation of the Share Purchase Agreement in October 2017 ( 1,095 not not no As of December 31, 2018, At-the-Market Program (ATM Program) Stifel ATM Program On February 11, 2013, may may three $25 not If we issued a sale notice to Stifel, we may may 3.0% During 2017, 42,357 $1.1 $1.0 Effective with our transition to the OTCQB® Market (OTCQB) tier in early May 2017, no 401 We have a voluntary 401 401 2017, 8 December 31, 2017, 7,561 401 December 31, 2017 $0.1 2018, not Common Shares Reserved for Future Issuance Common shares reserved for potential future issuance upon exercise of warrants The chart below summarizes shares of our common stock reserved for future issuance upon the exercise of warrants: December 31, Expiration (in thousands, except price per share data) 2018 2017 Exercise Price Date Investors - Aerosurf 2,963 - $ - 02/14/24 Investors - December 2018 financing - long-term 3,889 - $ 4.05 12/04/23 Investors - December 2018 financing - short-term 2,004 - $ 3.68 06/24/20 Battelle - 2018 payables restructuring agreement (1) 75 - $ 6.50 12/07/23 Panacea Venture Management Company Ltd. 188 - $ 4.00 07/02/23 LPH II Investments Limited 135 - $ 5.52 04/04/25 Investors - February 2017 financing 352 352 $ 27.40 02/15/24 Investors - July 2015 financing 240 240 $ 196.00 07/22/22 Battelle - 2014 collaboration agreement (1) 4 4 $ 1,400.00 10/10/24 Total 9,850 596 ( 1 See 16 Common shares reserved for potential future issuance upon exercise of stock options or granting of additional equity incentive awards At the 2017 2011 “2011 37,500. October 25, 2017 1.75 November 13, 2017. December 24, 2018, 4.2 As of December 31, 2018 2017, 1.5 1.6 2011 Common shares reserved for potential future issuance under our 401 As of December 31, 2018 2017, 807 401

Note 15 - Stock Options and Sto

Note 15 - Stock Options and Stock-based Employee Compensation	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	Note 9 Stock Options and Stock-Based Employee Compensation We recognize in our condensed consolidated financial statements all stock-based awards to employees and non-employee directors based on their fair value on the date of grant, calculated using the Black-Scholes option-pricing model. Compensation expense related to stock-based awards is recognized ratably over the vesting period, which for employees is typically three six 18 A summary of activity under our long-term incentive plan is presented below: (in thousands, except for weighted-average data) Stock Options Shares Weighted- Weighted- Outstanding at January 1, 2019 4,417 $ 6.73 Granted 1,144 4.20 Forfeited or expired (5 ) 467.57 Outstanding at September 30, 2019 5,556 $ 5.80 9.2 Vested and exercisable at September 30, 2019 70 $ 128.45 6.3 Vested and expected to vest at September 30, 2019 5,245 $ 5.79 9.2 (in thousands, except for weighted-average data) Restricted Stock Units Shares Weighted- Unvested at January 1, 2019 151 $ 4.29 Awarded 249 3.95 Vested (95 ) 3.95 Cancelled (144 ) 4.33 Unvested at September 30, 2019 161 $ 4.04 The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing formula based on the following weighted average assumptions: Nine Months Ended 2019 Weighted average expected volatility 95% Weighted average expected term (in years) 6.6 Weighted average risk-free interest rate 2.6% Expected dividends - The table below summarizes the total stock-based compensation expense included in the condensed consolidated statements of operations for the periods presented: Three Months Ended Nine Months Ended (in thousands) 2019 2018 2019 2018 Research and development $ 574 $ 29 $ 1,613 $ 169 General and administrative 1,365 116 3,595 534 Total $ 1,939 $ 145 $ 5,208 $ 703	Note 15 Stock Options and Stock-based Employee Compensation Long-Term Incentive Plans We have the 2011 2007 There are 6.1 2011 1.5 may An administrative committee (the Committee – currently the Compensation Committee of the Board of Directors) or Committee delegates may may Stock options and restricted stock units (RSUs) outstanding and available for future issuance are as follows: December 31, (in thousands) 2018 2017 Stock Options and RSUs Outstanding 2011 Plan 4,558 263 Non-Plan 10 10 Total Outstanding 4,568 273 Available for Future Grants under 2011 Plan 1,453 1,623 No 2011 may three first 10 February 1, 2016. 5635 4 three first 10 A summary of activity under our long-term incentive plans is presented below: Weighted- Weighted- Average (in thousands, except for weighted-average data) Average Remaining Stock Options Shares Exercise Contractual Outstanding at January 1, 2018 84 $ 163.20 Granted 4,337 4.22 Forfeited or expired (4 ) 617.75 Outstanding at December 31, 2018 4,417 $ 6.73 9.9 Vested and exercisable at December 31, 2018 63 $ 171.87 6.5 Vested and expected to vest at December 31, 2018 4,243 $ 6.78 9.9 (in thousands, except for weighted-average data) Restricted Stock Units Shares Weighted- Unvested at January 1, 2018 190 $ 4.33 Awarded 56 4.22 Vested (95 ) 4.33 Unvested at December 31, 2018 151 $ 4.29 Based upon application of the Black-Scholes option-pricing formula described below, the weighted-average grant-date fair value of options granted during the years ended December 31, 2018 2017 $3.39 $17.44, December 31, 2018 2017 $4.22 $4.33, December 31, 2018 $0. Stock-Based Compensation We recognized stock-based compensation expense in accordance with ASC Topic 718 $1.0 $1.6 December 31, 2018 2017. Stock-based compensation expense was classified as follows: Year Ended (in thousands) 2018 2017 Research and development $ 232 $ 837 Selling, general and administrative 723 724 Total $ 955 $ 1,561 Under the 2011 may October 2017 ( see 14 2011 $0.4 2017. The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing formula that uses assumptions noted in the following table. Expected volatilities are based upon the historical volatility of our common stock and other factors. We also use historical data and other factors to estimate option exercises, employee terminations and forfeiture rates. The risk-free interest rates are based upon the US Treasury yield curve in effect at the time of the grant. Year Ended 2018 2017 Weighted average expected volatility 93% 79% Weighted average expected term (in years) 7.0 6.6 Weighted average risk-free interest rate 2.7% 2.2% Expected dividends - - The total fair value of the underlying shares of the options vested during 2018 2017 $0.6 $1.9 December 31, 2018, $13.9 2011 2.9

Note 16 - Collaboration, Licens

Note 16 - Collaboration, Licensing and Research Funding Agreements	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Corporate Partnership, Licensing and Research Funding Agreements [Text Block]	Note 16 Collaboration, Licensing and Research Funding Agreements Collaboration Agreement Battelle Memorial Institute In October 2014, 3 2 2b three 3 3 3 first two $25 $35 In December 2018, See 9 December 2018 Licensing and Research Funding Agreements Lee’s Pharmaceutical (HK) Ltd. In June 2017, KL4 2012 12 August 2017 Under the License Agreement, Lee’s made an upfront payment to us of $1 may $37.5 may 3 In August 2017, $3.9 October 31, 2017, $10 November 1, 2017. $35.8 We will be eligible to receive tiered royalties based on a percent of Net Sales, depending on the product, in the range of high single to low-to-mid double-digit percentages. Royalties are payable on a country-by-country basis until the latest of (A) the expiration of the last valid patent claim covering the product in the country of sale, (B) the expiration or revocation of any applicable regulatory exclusivity in the country of sale, and (C) ten 10 first three one Under the License Agreement, Lee’s will be responsible for all activities related to development, regulatory approval and commercialization of KL4 ten 10 first first first first not Accounting Analysis under ASC 606 In evaluating the License Agreement in accordance with ASC Topic 606, KL4 606 10 25 16A, We concluded that the licensing rights were not not not not With respect to Amendment No. 1, 2014 09, $1 $0.3 No. 1. $1.3 KL4 November 2017 June 2019. Regulatory and commercialization milestones were excluded from the transaction price, as all milestone amounts were fully constrained under the guidance. As part of our evaluation of the constraint, we considered a number of factors in determining whether there is significant uncertainty associated with the future events that would result in the milestone payments. Those factors include: our financial position; ongoing delays in our development activities and with initiating our phase 3 2b 2015 not see 1A Consideration related to sales-based milestones and royalties will be recognized when the related sales occur, provided that the reported sales are reliably measurable and that we have no Philip Morris USA Inc. and Philip Morris Products S.A. Under license agreements with Philip Morris USA Inc. (PMUSA) and Philip Morris Products S.A. (PMPSA), we hold exclusive worldwide licenses to the ADS technology for use with pulmonary surfactants (alone or in combination with any other pharmaceutical compound(s)) for all respiratory diseases and conditions (the foregoing uses in each territory, the Exclusive Field), and an exclusive license in the US for use with certain non-surfactant drugs to treat a wide range of pediatric and adult respiratory indications in hospitals and other health care institutions. We generally are obligated to pay royalties at a rate equal to a low single-digit percent of sales of products sold in the Exclusive Field (as defined in the license agreements) in the territories, including sales of aerosol devices that are not 2014, 2017, $300,000 $487,500 $300,000 $187,500 2016 2018, $400,000 Johnson & Johnson and Ortho Pharmaceutical Corporation We, Johnson & Johnson (J&J) and its wholly-owned subsidiary, Ortho Pharmaceutical Corporation, are parties to a license agreement granting to us an exclusive worldwide license to the J&J proprietary KL4 $2.5 $1.0 $0.5 2012 Laboratorios del Dr. Esteve, S.A. We have a strategic alliance with Laboratorios del Dr. Esteve, S.A. (Esteve) for the development, marketing and sales of a broad portfolio of potential KL4 May 2002 January 2013. KL4 3 2004 10% $20 KL4 Università degli Studi di Milano-Bicocca Effective April 13, 2015, Ca2 2a SERCA2a SERCA2a three no Under the collaboration agreement, intellectual property resulting from the collaboration, including patents and know-how, will be jointly owned by the parties. For the development of any new SERCA2a 12 not 0.1 $0.1 SERCA2a 1.5 $1.7 ten first Also, under the collaboration agreement, we have provided funds aggregating € 0.2 $0.2 2019.

Note 17 - Related Party Transac

Note 17 - Related Party Transactions	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	Note 17 Related Party Transactions Lee’s Pharmaceutical Holdings Limited As of December 31, 2018 2017, 40% 73%, From June 2017 December 2018 ● In June 2017, see 16 ● In October 2017, $10 see 14 ● During 2018, see 11 ● In April 2018, $2.6 see 14 ● In conjunction with the CVie Acquisition in December 2018, 49% see 3 ● In December 2018, $6.0 see 11 ● Our $4.5 see 11 Panacea Venture and KPCB-China Mr. James Huang, who in connection with the CVie Acquisition in December 2018 2011, 2018 ● In July 2018, $1.5 December 2018 ( see 12 ● In December 2018, 114,415 ● In December 2018, 27% see 3 ● In December 2018, see 14 As of December 31, 2018, 14%

Note 18 - Commitments

Note 18 - Commitments	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Commitments Disclosure [Text Block]	Note 18 Commitments Operating Leases Our operating leases consist primarily of a facility leases for our operations in Warrington, Pennsylvania and Taipei, Taiwan. We maintain our corporate headquarters and operations in Warrington, Pennsylvania. The facility serves as the main operating facility for drug and device development, regulatory, analytical technical services, research and development, and administration. We also maintain offices in Taipei, Taiwan, the former headquarters of CVie Therapeutics, where we perform certain manufacturing development and preclinical activities related to our cardiovascular drug product candidates. In February 2018, 30,506 21,189 $225,000 $140,000. December 31, 2018 $2.1 Rent expense under these leases was $0.8 $0.7 December 31, 2018 2017, Strategic and Retention Bonus In November 2018, Under the terms of the Strategic and Retention Bonus, an Eligible Transaction (as that term is defined under the program) means either (a) a strategic transaction consisting of a merger that would advance our strategic needs, including by potentially allowing for diversification of our product candidates, or (b) an acquisition; and, in addition, one nine $30 2018 $45 20% $30 two first five second nine With completion of the CVie Acquisition and the $39 December 21, 2018, $1.4 first $0.7 December 2018. $0.7 nine September 2019.

Note 19 - Litigation

Note 19 - Litigation	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Legal Matters and Contingencies [Text Block]	Note 19 Litigation We are not We have from time to time been involved in disputes and proceedings arising in the ordinary course of business, including in connection with the conduct of our clinical trials. In addition, as a public company, we are also potentially susceptible to litigation, such as claims asserting violations of securities laws. Any such claims, with or without merit, if not no not

Note 20 - Income Taxes

Note 20 - Income Taxes	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Income Tax Disclosure [Text Block]	Note 20 Income Taxes Since our inception, we have never recorded a provision or benefit for federal and state income taxes. The reconciliation of the income tax benefit computed at the federal statutory rates to our recorded tax benefit for the years ended December 31, 2018 2017 December 31, (in thousands) 2018 2017 Income tax benefit, statutory rates $ (4,312 ) $ (6,272 ) State taxes on income, net of federal benefit (535 ) (398 ) Impact of tax reform 5 71,151 Research and development tax credit (351 ) (797 ) Foreign rate differential 24 - Employee related 2,875 953 Interest related 186 (147 ) Income tax expense / (benefit), statutory rates (2,108 ) 64,490 Valuation allowance 2,108 (64,490 ) Income tax benefit, net $ - $ - During 2017, 2017 2017 2017 118, December 31, 2018. fourth 2018 not The tax effects of temporary differences that give rise to deferred tax assets and deferred tax liabilities, at December 31, 2018 2017, December 31, (in thousands) 2018 2017 Long-term deferred assets: Net operating loss carryforwards (federal and state) $ 176,759 $ 168,263 Research and development tax credit 16,718 16,813 Compensation expense on stock 1,121 1,191 Charitable contribution carryforward - 5 Other accrued 1,016 2,547 Deferred revenue 57 317 Depreciation 309 297 Total long-term deferred tax assets 195,980 189,433 Long-term deferred liabilities: IPR&D (15,476 ) - Total long-term deferred tax liabilities (15,476 ) - Valuation allowance (195,980 ) (189,433 ) Deferred tax liabilities, net $ (15,476 ) $ - We are in a net deferred tax liability position at December 31, 2018. December 31, 2017 not December 31, 2018 2017, 2018 2017. At December 31, 2018 2017, $606.6 $590.0 $16.7 $16.8 2037. At December 31, 2018 2017, $584.8 $567.7 $583.9 $570.2 6 Utilization of net operating loss (NOL) and research and development (R&D) credit carryforwards may 382 1986 may may A full valuation allowance has been provided against our deferred tax assets and, if a future assessment requires an adjustment, an adjustment would be offset by an adjustment to the valuation allowance. Thus, there would be no

Note 21 - Selected Quarterly Fi

Note 21 - Selected Quarterly Financial Data (Unaudited)	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Quarterly Financial Information [Text Block]	Note 21 Selected Quarterly Financial Data (Unaudited) The following tables contain unaudited statement of operations information for each quarter of 2018 2017. not 2018 Quarters Ended: (in thousands, except per share data) Mar. 31 June 30 Sept. 30 Dec. 31 Total Year Revenues: Grant revenue $ - $ 695 $ 70 $ - $ 765 License revenue with affiliate 204 356 159 304 1,023 Total revenues 204 1,051 229 304 1,788 Expenses: Research and development 3,118 2,879 2,197 2,368 10,562 Selling, general and administrative 1,926 1,208 1,500 2,787 7,421 Total expenses 5,044 4,087 3,697 5,155 17,983 Operating loss (4,840 ) (3,036 ) (3,468 ) (4,851 ) (16,195 ) Other income / (expense), net 328 (16 ) (459 ) (4,191 ) (4,338 ) Net (loss) / income $ (4,512 ) $ (3,052 ) $ (3,927 ) $ (9,042 ) $ (20,533 ) AEROSURF warrant dividend - - - (12,505 ) (12,505 ) Deemed dividend on preferred stock - - - (1,718 ) (1,718 ) Net (loss) / income attributable to common shareholders $ (4,512 ) $ (3,052 ) $ (3,927 ) $ (23,265 ) $ (34,756 ) Net (loss) / income per common share - basic $ (1.40 ) $ (0.81 ) $ (1.04 ) $ (3.24 ) $ (7.74 ) Net (loss) / income per common share - diluted $ (1.40 ) $ (0.81 ) $ (1.04 ) $ (3.24 ) $ (7.74 ) Weighted average number of common shares outstanding - basic 3,227 3,751 3,769 7,191 4,493 Weighted average number of common shares outstanding - diluted 3,227 3,751 3,769 7,191 4,493 2017 Quarters Ended: (in thousands, except per share data) Mar. 31 June 30 Sept. 30 Dec. 31 Total Year Revenues: Grant revenue $ 219 $ 1,147 $ 17 $ - $ 1,383 License revenue with affiliate - - - 102 102 Total revenues 219 1,147 17 102 1,485 Expenses: Research and development 6,413 5,483 3,062 2,418 17,376 Selling, general and administrative 1,922 1,804 1,749 1,182 6,657 Total expenses 8,335 7,287 4,811 3,600 24,033 Operating loss (8,116 ) (6,140 ) (4,794 ) (3,498 ) (22,548 ) Other income / (expense), net (608 ) (612 ) (649 ) 5,971 4,102 Net (loss) / income $ (8,724 ) $ (6,752 ) $ (5,443 ) $ 2,473 $ (18,446 ) Deemed dividend on preferred stock (3,604 ) (532 ) (2,234 ) - (6,370 ) Net (loss) / income attributable to common shareholders $ (12,328 ) $ (7,284 ) $ (7,677 ) $ 2,473 $ (24,816 ) Net (loss) / income per common share - basic $ (27.40 ) $ (14.37 ) $ (10.53 ) $ 1.03 $ (24.14 ) Net (loss) / income per common share - diluted $ (27.40 ) $ (14.37 ) $ (10.53 ) $ 0.97 $ (24.14 ) Weighted average number of common shares outstanding - basic 450 507 729 2,405 1,028 Weighted average number of common shares outstanding - diluted 450 507 729 2,540 1,028 F- 33

Note 1 - The Company and Desc_2

Note 1 - The Company and Description of Business	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	Note 1 The Company and Description of Business Windtree Therapeutics, Inc. (referred to as “we,” “us,” or the “Company”) is a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases. Through 2018, KL4 December 2018, may Our four 1 2 KL4 3 KL4 4 2 3. 2a See 3 The reader is referred to, and encouraged to read in its entirety, Item 1 10 December 31, 2018 April 16, 2019, 10 April 23, 2019 ( 2018 10 10	Note 1 The Company and Description of Business Windtree Therapeutics, Inc. (referred to as “we,” “us,” or the “Company”) is a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute pulmonary and cardiovascular diseases. Historically, our focus has been on the development of our proprietary KL4 December 2018 ( see 3 Our four 1 2 KL4 3 KL4 4 Heart failure is a chronic, progressive disease resulting from structural or functional cardiac abnormalities and is characterized by inadequate pumping function of the heart that results in fluid accumulation manifesting as pulmonary congestion, peripheral edema and congestion in other parts of the body. Insufficient cardiac output can result in inadequate peripheral perfusion that increases the risk of other organ dysfunction such as renal failure. Heart failure commonly but episodically worsens to a point of decompensation, a condition called ADHF. We are developing istaroxime for the treatment of ADHF. Istaroxime has a dual mechanism of action referred to as luso-inotropic, that may two 2 may 2019, AEROSURF (lucinactant for inhalation) is an investigational combination drug/device product that we are developing to improve the management of RDS in premature infants who may not may may KL4 2017, 2b not 72 24% 50 2 50 2019, 3 not 2b KL4 We are also assessing potential development pathways to secure marketing approval for lyophilized KL4 KL4 KL4 2012 second 2019. may not We also believe that our lyophilized KL4 may Our fourth 20% 25% may may may three 2b two one one no 2019, The reader is referred to, and encouraged to read in its entirety, “Item 1 10

Note 2 - Basis of Presentatio_2

Note 2 - Basis of Presentation	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Notes to Financial Statements
Basis of Accounting [Text Block]	Note 2 Basis of Presentation These interim unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the US (US GAAP) for interim financial information in accordance with the instructions to Form 10 not three nine September 30, 2019 not may December 31, 2019. no December 31, 2018. December 31, 2018 2018 10 10	Note 2 Basis of Presentation The consolidated financial statements are prepared in accordance with accounting principles generally accepted in the US (US GAAP) and include accounts of Windtree and its wholly-owned subsidiaries. Intercompany balances and transactions have been eliminated in consolidation. In the opinion of management, all adjustments (consisting of normally recurring accruals) considered for fair presentation have been included. When necessary, prior year’s consolidated financial statements have been reclassified to conform to the current year presentation.

Note 3 - Liquidity Risks and Ma

Note 3 - Liquidity Risks and Management's Plans	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Notes to Financial Statements
Liquidity Disclosures [Text Block]	Note 3 Liquidity Risks and Management’s Plans As of September 30, 2019, $4.4 $16.3 $7.8 see 7 October 24, 2019, $1.0 November 2019 We have an immediate need for additional capital to continue our operations. Even if we are able to secure such additional capital in the near term, we expect to continue to incur significant losses and will require significant additional capital to support our operations, advance our clinical development programs, and satisfy existing obligations. We currently only have cash and cash equivalent resources to fund our business operations through late- November 2019, not one To alleviate the conditions that raise substantial doubt about our ability to continue as a going concern, management plans, and is currently actively engaged in discussions with various parties, including our largest shareholders, seeking to secure additional capital, potentially through one none no may not none November 2019 not one The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business, and do not As of September 30, 2019, 120.0 5.0 72.0 5.0 not	Note 4 Liquidity Risks and Management’s Plans As of December 31, 2018, $11.2 $14.0 $20.6 $8.0 see 11 April 5, 2019, October 2019. Although we believe that the December 2018 $39 may October 2019, not one To alleviate the conditions that raise substantial doubt about our ability to continue as a going concern, management plans to raise additional capital through a combination of public or private equity offerings and strategic transactions, including but not none no none not one The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business, and do not As of December 31, 2018, 120 5 72.0 5.0 not

Note 4 - Summary of Significant

Note 4 - Summary of Significant Accounting Policies	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Notes to Financial Statements
Significant Accounting Policies [Text Block]	Note 4 Summary of Significant Accounting Policies Principles of C onsolidation The condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the US (US GAAP) and include accounts of Windtree Therapeutics, Inc. and its wholly-owned subsidiaries, CVie Investments, CVie Therapeutics, and a presently inactive subsidiary, Discovery Laboratories, Inc. Business C ombinations We follow the acquisition method for an acquisition of a business where the purchase price is allocated to the assets acquired and liabilities assumed based on their estimated fair values at the dates of acquisition. The excess of the fair value of purchase consideration over the fair value of the assets acquired and liabilities assumed is recorded as goodwill. Such valuations require management to make significant estimates and assumptions, especially with respect to intangible assets. Management’s estimate of fair value is based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and as such, actual results may Goodwill and I ntangible A ssets We record acquired identified intangibles, which includes intangible assets (such as goodwill and other intangibles), based on estimated fair value. The acquired in-process research and development (IPR&D) assets are considered indefinite-lived intangible assets until completion or abandonment of the associated research and development efforts. IPR&D is not may September 30, 2019 December 31, 2018: (in thousands) Carrying Value Istaroxime drug candidate $ 22,340 Rostafuroxin drug candidate 54,750 Total $ 77,090 Goodwill represents the excess of the purchase price over the fair value of assets acquired and liabilities assumed in a business combination and is not may not not Foreign C urrency T ransactions The functional currency for our foreign subsidiaries is US dollars. We remeasure monetary assets and liabilities that are not $0.1 $0.4 three nine September 30, 2019. no three nine September 30, 2018. Use of E stimates The preparation of financial statements, in conformity with US GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Marketable S ecurities Marketable securities consist of investments in US Treasury securities. Management determines the appropriate classification of these securities at the time they are acquired and evaluates the appropriateness of such classifications at each balance sheet date. We classify investments as available-for-sale pursuant to Financial Accounting Standards Board (FASB) Accounting Standard Codification (ASC) 320, three September 30, 2019, $14,000 $12,000 nine September 30, 2019, $75,000 no three nine September 30, 2018. We review investments for other-than-temporary impairment whenever the fair value of an investment is less than the amortized cost and evidence indicates that an investment’s carrying amount is not not Available-for-sale marketable securities are classified as marketable securities, current or marketable securities, non-current depending on the contractual maturity date of the individual available-for-sale security. Leases Effective January 1, 2019, 842, Leases 842 not 840, Leases At the inception of an arrangement, we determine whether an arrangement is, or contains, a lease based on the unique facts and circumstances present in the arrangement. An arrangement is, or contains, a lease if the arrangement conveys the right to control the use of an identified asset for a period of time in exchange for consideration. Leases with a term greater than one not 12 not Operating lease liabilities and their corresponding operating lease right-of-use assets are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may not 842, Restructured D ebt L iability – Co ntingent M ilestone P ayment In conjunction with the November 2017 s ee, 8 $15 October 27, 2017 ( not Research and D evelopment We account for research and development expense by the following categories: (a) product development and manufacturing, (b) clinical medical and regulatory operations, and (c) direct preclinical and clinical development programs. Research and development expense includes personnel, facilities, manufacturing and quality operations, pharmaceutical and device development, research, clinical, regulatory, other preclinical and clinical activities and medical affairs. Research and development costs are charged to operations as incurred in accordance with ASC Topic 730, Research and Development Net L oss per C ommon S hare Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding for the period. Diluted net loss per common share is computed by giving effect to all potentially dilutive securities outstanding for the period. As of September 30, 2019 2018, 15.6 1.3 three nine September 30, 2019 2018, Income T axes We account for income taxes in accordance with ASC Topic 740, Accounting for Income Taxes We use a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Because we have never realized a profit, management has fully reserved the net deferred tax asset since realization is not Recently A dopted A ccounting S tandards In February 2016, No. 2016 02, Leases 2016 02 2016 02 842 840, Leases 842 2018. January 1, 2019 not not January 1, 2019. 840 ASC 842 not 12 not The adoption of this standard resulted in the recognition of operating lease liabilities and related right-of-use assets on our condensed consolidated balance sheets of $2.2 $2.0 842 $72,000 $139,000 not 10 In January 2017, No. 2017 04, 350 second December 15, 2019 January 1, 2019 December 31, 2019. Recently Issued Accounting Standards In August 2018, No. 2018 13, 820 2018 13 820. no 1 2 3 3 3 2018 13 December 15, 2019. 2018 13	Note 5 Accounting Policies and Recent Accounting Pronouncements Principles of consolidation The consolidated financial statements are prepared in accordance with accounting principles generally accepted in the US (US GAAP) and include accounts of Windtree Therapeutics, Inc. and its wholly-owned subsidiaries, CVie Investments Limited and its wholly-owned subsidiary, CVie Therapeutics Limited; and a presently inactive subsidiary, Discovery Laboratories, Inc. (formerly known as Acute Therapeutics, Inc.). Business c ombinations We follow the acquisition method for an acquisition of a business where the purchase price is allocated to the assets acquired and liabilities assumed based on their estimated fair values at the dates of acquisition. The excess of the fair value of purchase consideration over the fair value the assets acquired and liabilities assumed is recorded as goodwill. Such valuations require management to make significant estimates and assumptions, especially with respect to intangible assets. Management’s estimate of fair value is based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and as such, actual results may Goodwill and i ntangible a ssets We record acquired identified intangibles, which includes intangible assets (such as goodwill and other intangibles), based on estimated fair value. The acquired in-process research and development (“IPR&D”) assets are considered indefinite-lived intangible assets until completion or abandonment of the associated research and development efforts. IPR&D is not may December 31, 2018: (in thousands) Estimated Fair Value Istaroxime drug candidate $ 22,340 Rostafuroxin drug candidate 54,750 Total $ 77,090 Goodwill represents the excess of the purchase price over the fair value assets acquired and liabilities assumed in a business combination and is not may not not Foreign c urrenc y transactions The functional currency for our foreign subsidiaries is US Dollars. We remeasure monetary assets and liabilities that are not $0.1 December 31, 2018. no December 31, 2017. Use of estimates The preparation of financial statements, in conformity with accounting principles generally accepted in the U. S., requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Cash and cash equivalents Cash and cash equivalents are held in at domestic and foreign financial institutions and consist of liquid investments and money market funds with a maturity from date of purchase of 90 Marketable securities Marketable securities consist of investments in US Treasury securities. Management determines the appropriate classification of these securities at the time they are acquired and evaluates the appropriateness of such classifications at each balance sheet date. We classify investments as available-for-sale pursuant to Financial Accounting Standards Board (“FASB”) Accounting Standard Codification (“ASC”) 320, no December 31, 2018 2017. no December 31, 2018 2017. We review investments for other-than-temporary impairment whenever the fair value of an investment is less than the amortized cost and evidence indicates that an investment’s carrying amount is not not Available-for-sale marketable securities are classified as marketable securities, current or marketable securities, non-current depending on the contractual maturity date of the individual available-for-sale security. Fair value of financial instruments Our financial instruments consist principally of cash and cash equivalents and restricted cash. The fair values of our cash equivalents are based on quoted market prices. The carrying amount of cash equivalents is equal to their respective fair values at December 31, 2018 2017, Property and equipment Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets (generally three ten Restricted cash Restricted cash consists principally of a $140,000 May 26, 2004 $31,000 see, 18 Long-lived assets Our long-lived assets, primarily consisting of intangible assets, are reviewed for impairment when events or changes in circumstances indicate the carrying amount of an asset may not No December 31, 2018 2017 no not Collaborative arrangements We account for collaborative arrangements in accordance with applicable accounting guidance provided in ASC Topic 808, Collaborative Arrangements See, 16 Restructured debt liability – contingent milestone payment In conjunction with the November 2017 see, 13 $15 October 27, 2017 ( not Deferred revenue Deferred revenue represents amounts received prior to satisfying the revenue recognition criteria ( see 12 not 12 Deferred revenue primarily consists of amounts related to an upfront license fee received in July 2017 see 16 Revenue recognition Effective January 1, 2018, 606, 606, In accordance with ASC Topic 606, 606, five (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. We only apply the five 606, We have concluded that our government grants are not 606 not 958 605, Not not In the absence of applicable guidance under US GAAP, effective January 1, 2018, We believe this policy is consistent with the overarching premise in ASC Topic 606, no 606. 606. Prior to January 1, 2018, not no Research and development We account for research and development expense by the following categories: (a) product development and manufacturing, (b) medical and regulatory operations, and (c) direct preclinical and clinical development programs. Research and development expense includes personnel, facilities, manufacturing and quality operations, pharmaceutical and device development, research, clinical, regulatory, other preclinical and clinical activities and medical affairs. Research and development costs are charged to operations as incurred in accordance with Accounting Standards Codification (ASC) Topic 730, Research and Development Stock-based compensation Stock-based compensation is accounted for under the fair value recognition provisions of ASC Topic 718, Stock Compensation 718 See 15 Warrant accounting We account for common stock warrants in accordance with applicable accounting guidance provided in ASC Topic 815, Derivatives and Hedging – Contracts in Entity’s Own Equity 815 Income taxes We account for income taxes in accordance with ASC Topic 740, We use a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Because we have never realized a profit, management has fully reserved the net deferred tax asset since realization is not Beneficial Conversion Feature A beneficial conversion feature arises when a debt or equity security is issued with an embedded conversion option that is beneficial to the investor (or in the money) at inception due to the conversion option having an effective conversion price that is less than the fair value of the underlying stock at the commitment date. Preferred Stock The issuance of Series A Convertible Preferred Stock (Preferred Shares) in the first 2017 14 $3.6 one first 2017. An additional discount to the Preferred Shares of $4.5 December 31, 2018 December 31, 2017, $1.7 $2.8 December 31, 2018, no Convertible Note The issuance on July 2, 2018 $1.5 $1.5 $0.4 $0.4 $1.5 see 11 December 27, 2018, $1.5 $0.4 $5.11 $4.00, 375,000 Net loss per common share Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding for the period. Diluted net loss per common share is computed by giving effect to all potentially dilutive securities outstanding for the period. For the years ended December 31, 2018 2017, 14.4 1.0 December 31, 2018 2017, We do not Concentration of Suppliers We currently obtain the active pharmaceutical ingredients (APIs) of our KL4 third KL4 one Business segments We currently operate in one one not Recent Accounting Pronouncements Recently Adopted Accounting Standards In May 2014, 2014 09, Revenue from Contracts with Customers (Topic 606 606 2014 09, January 1, 2018 June 2017, 2014 09 no no See, 16 In May 2017, 2017 09, Compensation—Stock Compensation (Topic 718 December 31, 2018 2017 09 January 1, 2018 not 2018 In August 2016, 2016 15, Statement of Cash Flows (Topic 230 eight one December 31, 2018 2016 15 January 1, 2018 not 2018 In January 2017, 2017 01, Business Combinations (Topic 805 first not not December 31, 2018 2017 01 January 1, 2018 not 2018 Recent Accounting Pronouncements In February 2016, 2016 02, Leases 842 January 1, 2019. not In January 2017, 2017 04, Intangibles - Goodwill and Other: Simplifying the Test for Goodwill Impairment 2017 04 second two not 2017 04 December 15, 2019; 2017 04 not

Note 5 - License Revenue with A

Note 5 - License Revenue with Affiliate	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	Note 5 License Revenue with Affiliate Three Months Ended Nine Months Ended (in thousands) 2019 2018 2019 2018 License revenue with affiliate $ - $ 159 $ 198 $ 719 License revenue with affiliate represents revenue from a License Agreement with Lee’s Pharmaceutical (HK) Ltd. (Lee’s (HK)), an affiliate of our largest shareholder, Lee’s Pharmaceutical Holdings Limited (Lee’s), and constitutes a contract with a customer accounted for in accordance with ASC Topic 606. June 30, 2019, no	Note 6 License Revenue with Affiliate Year Ended December 31, (in thousands) 2018 2017 License revenue with affiliate $ 1,023 $ 102 License revenue with affiliate for years ended December 31, 2018 2017 606, January 1, 2018 ( see 5 16 no 606.

Note 6 - Fair Value of Financia

Note 6 - Fair Value of Financial Instruments	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Notes to Financial Statements
Fair Value Disclosures [Text Block]	Note 6 Fair Value of Financial Instruments Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on three first two ● Level 1 ● Level 2 1 not ● Level 3 no Fair Value on a Recurring Basis The tables below categorize assets and liabilities measured at fair value on a recurring basis for the periods presented: Fair Value Fair value measurement using September 30, (in thousands) 2019 Level 1 Level 2 Level 3 Assets: Cash and cash equivalents $ 4,437 $ 4,437 $ - $ - U.S. Treasury notes - - - - Certificate of deposit 154 154 - - Total Assets $ 4,591 $ 4,591 $ - $ - Fair Value Fair value measurement using December 31, (in thousands) 2018 Level 1 Level 2 Level 3 Assets: Cash and cash equivalents $ 5,234 $ 5,234 $ - $ - U.S. Treasury notes 19,912 19,912 - - Certificate of deposit 171 171 - - Total Assets $ 25,317 $ 25,317 $ - $ -	Note 7 Fair Value Measurements Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on three first two ● Level 1 ● Level 2 1 not ● Level 3 no Fair Value on a Recurring Basis Assets and liabilities measured at fair value on a recurring basis are categorized in the table below as of December 31, 2018 2017: Fair Value Fair value measurement using December 31, (in thousands) 2018 Level 1 Level 2 Level 3 Assets: Cash and cash equivalents $ 5,234 $ 5,234 $ - $ - U.S. Treasury notes 19,912 $ 19,912 Certificate of deposit 171 171 - - Total Assets $ 25,317 $ 25,317 $ - $ - Fair Value Fair value measurement using December 31, (in thousands) 2017 Level 1 Level 2 Level 3 Assets: Cash and cash equivalents $ 1,815 $ 1,815 $ - $ - Certificate of deposit 225 225 - - Total Assets $ 2,040 $ 2,040 $ - $ -

Note 7 - Loans Payable

Note 7 - Loans Payable	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Notes to Financial Statements
Short-term Debt [Text Block]	Note 7 Loan s Payable In January 2018 March 2018, $1.5 $1.0 one 6% December 31, 2018. March 1, 2018 ( December 5, 2018, $6.0 $1.5 $1.0 Assumption of bank debt as part of the CVie Acquisition As part of the CVie Acquisition, we assumed approximately $4.5 March 2020. In September 2016, 12 $2.9 $5.8 September 2017. 110% not 90 0.91%. September 11, 2019 six March 11, 2020. 2021. As of September 30, 2019, $4.5 Assumption of Lee's debt as part of the CVie Acquisition As part of the CVie Acquisition, we assumed approximately $3.5 From April 24, 2018 November 16, 2018, four $3.5 4% one $0.5 April 2019; $0.3 September 2019; $0.2 October 2019; $2.5 November 2019. no April 30, 2021. During the quarter ended March 31, 2019, $0.45 April 2018 $50,000 April 2019. September 30, 2019, $3.0 Loan payable to Bank Direct Capital Finance In May 2019, $0.7 5.35% $80,000 March 2020. September 30, 2019, $0.4	Note 11 – Loan Payable In January 2018 March 2018, $1.5 $1.0 one 6% December 31, 2018. March 1, 2018 ( During the third fourth 2018, August 14, 2018 $0.3 August 29, 2018, $0.48 September 12, 2018 $0.5 September 27, 2018 $0.5 October 19, 2018 $0.43 November 2, 2018 $0.5 November 19, 2018 $0.35 December 5, 2018 $0.6 6% $30 March 31, 2019. Extinguishment of Loan Payable On December 21, 2018, $6.0 1,810,938 $3.3132 307,859 $3.68 597,610 $4.05 18 may 5 The conversion of the loan payable to LPH is treated as an extinguishment of debt and does not third $3.2 $9.2 December 21, 2018, $6.0 The balance of the loan payable to LPH of $160,000 $182,000 December 27, 2018. Assumption of bank debt as part of the CVie Acquisition As part of the CVie Acquisition, we assumed approximately $4.5 $138.0 March 2020. In September 2016, 12 $2.9 $90.0 $5.84 $180.0 September 2017. 110% not 90 0.91%. September 11, 2019 six March 11, 2020. not $4.5 As of December 31, 2018, $4.5 $138.0 Assumption of Lee’s debt as part of the CVie Acquisition As part of the CVie Acquisition, we assumed approximately $3.5 $106.2 From April 24, 2018 November 16, 2018, four $3.5 4% four one $0.5 April 2019; $0.3 September 2019; $0.2 October 2019; $2.5 November 2019. As of December 31, 2018, $3.5 $106.2

Note 8 - Restructured Debt Liab

Note 8 - Restructured Debt Liability	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Notes to Financial Statements
Long-term Debt [Text Block]	Note 8 Restructured Debt Liability September 30, December 31, (in thousands) 2019 2018 Restructured debt liability - contingent milestone payments $ 15,000 $ 15,000 On November 1, 2017, $25 25,000 $786.80 $2.5 71,111 2% $15 $15 see 4 not	Note 13 Restructured Debt Liability December 31, December 31, (in thousands) 2018 2017 Restructured debt liability - contingent milestone payments $ 15,000 $ 15,000 On November 1, 2017, $25 25,000 $786.80 $2.5 71,111 2% $15 $15 see 5 not

Note 9 - Stock Options and Stoc

Note 9 - Stock Options and Stock-based Employee Compensation	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	Note 9 Stock Options and Stock-Based Employee Compensation We recognize in our condensed consolidated financial statements all stock-based awards to employees and non-employee directors based on their fair value on the date of grant, calculated using the Black-Scholes option-pricing model. Compensation expense related to stock-based awards is recognized ratably over the vesting period, which for employees is typically three six 18 A summary of activity under our long-term incentive plan is presented below: (in thousands, except for weighted-average data) Stock Options Shares Weighted- Weighted- Outstanding at January 1, 2019 4,417 $ 6.73 Granted 1,144 4.20 Forfeited or expired (5 ) 467.57 Outstanding at September 30, 2019 5,556 $ 5.80 9.2 Vested and exercisable at September 30, 2019 70 $ 128.45 6.3 Vested and expected to vest at September 30, 2019 5,245 $ 5.79 9.2 (in thousands, except for weighted-average data) Restricted Stock Units Shares Weighted- Unvested at January 1, 2019 151 $ 4.29 Awarded 249 3.95 Vested (95 ) 3.95 Cancelled (144 ) 4.33 Unvested at September 30, 2019 161 $ 4.04 The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing formula based on the following weighted average assumptions: Nine Months Ended 2019 Weighted average expected volatility 95% Weighted average expected term (in years) 6.6 Weighted average risk-free interest rate 2.6% Expected dividends - The table below summarizes the total stock-based compensation expense included in the condensed consolidated statements of operations for the periods presented: Three Months Ended Nine Months Ended (in thousands) 2019 2018 2019 2018 Research and development $ 574 $ 29 $ 1,613 $ 169 General and administrative 1,365 116 3,595 534 Total $ 1,939 $ 145 $ 5,208 $ 703	Note 15 Stock Options and Stock-based Employee Compensation Long-Term Incentive Plans We have the 2011 2007 There are 6.1 2011 1.5 may An administrative committee (the Committee – currently the Compensation Committee of the Board of Directors) or Committee delegates may may Stock options and restricted stock units (RSUs) outstanding and available for future issuance are as follows: December 31, (in thousands) 2018 2017 Stock Options and RSUs Outstanding 2011 Plan 4,558 263 Non-Plan 10 10 Total Outstanding 4,568 273 Available for Future Grants under 2011 Plan 1,453 1,623 No 2011 may three first 10 February 1, 2016. 5635 4 three first 10 A summary of activity under our long-term incentive plans is presented below: Weighted- Weighted- Average (in thousands, except for weighted-average data) Average Remaining Stock Options Shares Exercise Contractual Outstanding at January 1, 2018 84 $ 163.20 Granted 4,337 4.22 Forfeited or expired (4 ) 617.75 Outstanding at December 31, 2018 4,417 $ 6.73 9.9 Vested and exercisable at December 31, 2018 63 $ 171.87 6.5 Vested and expected to vest at December 31, 2018 4,243 $ 6.78 9.9 (in thousands, except for weighted-average data) Restricted Stock Units Shares Weighted- Unvested at January 1, 2018 190 $ 4.33 Awarded 56 4.22 Vested (95 ) 4.33 Unvested at December 31, 2018 151 $ 4.29 Based upon application of the Black-Scholes option-pricing formula described below, the weighted-average grant-date fair value of options granted during the years ended December 31, 2018 2017 $3.39 $17.44, December 31, 2018 2017 $4.22 $4.33, December 31, 2018 $0. Stock-Based Compensation We recognized stock-based compensation expense in accordance with ASC Topic 718 $1.0 $1.6 December 31, 2018 2017. Stock-based compensation expense was classified as follows: Year Ended (in thousands) 2018 2017 Research and development $ 232 $ 837 Selling, general and administrative 723 724 Total $ 955 $ 1,561 Under the 2011 may October 2017 ( see 14 2011 $0.4 2017. The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing formula that uses assumptions noted in the following table. Expected volatilities are based upon the historical volatility of our common stock and other factors. We also use historical data and other factors to estimate option exercises, employee terminations and forfeiture rates. The risk-free interest rates are based upon the US Treasury yield curve in effect at the time of the grant. Year Ended 2018 2017 Weighted average expected volatility 93% 79% Weighted average expected term (in years) 7.0 6.6 Weighted average risk-free interest rate 2.7% 2.2% Expected dividends - - The total fair value of the underlying shares of the options vested during 2018 2017 $0.6 $1.9 December 31, 2018, $13.9 2011 2.9

Note 10 - Leases

Note 10 - Leases	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	Note 10 Leases Our operating leases consist primarily of facility leases for our operations in Warrington, Pennsylvania and Taipei, Taiwan. We maintain our corporate headquarters and operations in Warrington, Pennsylvania, with a remaining non-cancelable term of approximately three Throughout the term of our leases, we are responsible for paying certain variable lease costs, in addition to the rent, as specified in the lease, including a proportionate share of applicable taxes, operating expenses and utilities. The following table contains a summary of the lease costs recognized under ASC 842 three nine September 30, 2019: Three Months Ended Nine Months Ended (in thousands) 2019 2019 Operating lease cost $ 212 $ 677 Variable lease cost 5 17 Total lease cost $ 217 $ 694 Other Information Operating cash flows used for operating leases $ 227 $ 721 Operating lease liabilities arising from obtaining right-of-use assets $ 232 $ 364 Weighted average remaining lease term (in years) 2.4 2.4 Weighted average incremental borrowing rate 9.00 % 9.00 % Future minimum lease payments under our non-cancelable operating leases as of September 30, 2019, As of (in thousands) 2019 2019 (excluding the nine months ended September 30, 2019) $ 230 2020 849 2021 638 2022 179 2023 23 Thereafter - Total lease payments 1,919 Less imputed interest (184 ) Total operating lease liabilities at September 30, 2019 1,735

Note 11 - Subsequent Event

Note 11 - Subsequent Event	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Subsequent Events [Text Block]	Note 11 Subsequent Event Effective as of October 24, 2019, $1.0 October 28, 2019, 6% December 31, 2019. may may

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Principles of C onsolidation The condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the US (US GAAP) and include accounts of Windtree Therapeutics, Inc. and its wholly-owned subsidiaries, CVie Investments, CVie Therapeutics, and a presently inactive subsidiary, Discovery Laboratories, Inc.	Principles of consolidation The consolidated financial statements are prepared in accordance with accounting principles generally accepted in the US (US GAAP) and include accounts of Windtree Therapeutics, Inc. and its wholly-owned subsidiaries, CVie Investments Limited and its wholly-owned subsidiary, CVie Therapeutics Limited; and a presently inactive subsidiary, Discovery Laboratories, Inc. (formerly known as Acute Therapeutics, Inc.).
Business Combinations Policy [Policy Text Block]	Business C ombinations We follow the acquisition method for an acquisition of a business where the purchase price is allocated to the assets acquired and liabilities assumed based on their estimated fair values at the dates of acquisition. The excess of the fair value of purchase consideration over the fair value of the assets acquired and liabilities assumed is recorded as goodwill. Such valuations require management to make significant estimates and assumptions, especially with respect to intangible assets. Management’s estimate of fair value is based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and as such, actual results may	Business c ombinations We follow the acquisition method for an acquisition of a business where the purchase price is allocated to the assets acquired and liabilities assumed based on their estimated fair values at the dates of acquisition. The excess of the fair value of purchase consideration over the fair value the assets acquired and liabilities assumed is recorded as goodwill. Such valuations require management to make significant estimates and assumptions, especially with respect to intangible assets. Management’s estimate of fair value is based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and as such, actual results may
Goodwill and Intangible Assets, Policy [Policy Text Block]	Goodwill and I ntangible A ssets We record acquired identified intangibles, which includes intangible assets (such as goodwill and other intangibles), based on estimated fair value. The acquired in-process research and development (IPR&D) assets are considered indefinite-lived intangible assets until completion or abandonment of the associated research and development efforts. IPR&D is not may September 30, 2019 December 31, 2018: (in thousands) Carrying Value Istaroxime drug candidate $ 22,340 Rostafuroxin drug candidate 54,750 Total $ 77,090 Goodwill represents the excess of the purchase price over the fair value of assets acquired and liabilities assumed in a business combination and is not may not not	Goodwill and i ntangible a ssets We record acquired identified intangibles, which includes intangible assets (such as goodwill and other intangibles), based on estimated fair value. The acquired in-process research and development (“IPR&D”) assets are considered indefinite-lived intangible assets until completion or abandonment of the associated research and development efforts. IPR&D is not may December 31, 2018: (in thousands) Estimated Fair Value Istaroxime drug candidate $ 22,340 Rostafuroxin drug candidate 54,750 Total $ 77,090 Goodwill represents the excess of the purchase price over the fair value assets acquired and liabilities assumed in a business combination and is not may not not
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign C urrency T ransactions The functional currency for our foreign subsidiaries is US dollars. We remeasure monetary assets and liabilities that are not $0.1 $0.4 three nine September 30, 2019. no three nine September 30, 2018.	Foreign c urrenc y transactions The functional currency for our foreign subsidiaries is US Dollars. We remeasure monetary assets and liabilities that are not $0.1 December 31, 2018. no December 31, 2017.
Use of Estimates, Policy [Policy Text Block]	Use of E stimates The preparation of financial statements, in conformity with US GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.	Use of estimates The preparation of financial statements, in conformity with accounting principles generally accepted in the U. S., requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents, Policy [Policy Text Block]		Cash and cash equivalents Cash and cash equivalents are held in at domestic and foreign financial institutions and consist of liquid investments and money market funds with a maturity from date of purchase of 90
Marketable Securities, Policy [Policy Text Block]	Marketable S ecurities Marketable securities consist of investments in US Treasury securities. Management determines the appropriate classification of these securities at the time they are acquired and evaluates the appropriateness of such classifications at each balance sheet date. We classify investments as available-for-sale pursuant to Financial Accounting Standards Board (FASB) Accounting Standard Codification (ASC) 320, three September 30, 2019, $14,000 $12,000 nine September 30, 2019, $75,000 no three nine September 30, 2018. We review investments for other-than-temporary impairment whenever the fair value of an investment is less than the amortized cost and evidence indicates that an investment’s carrying amount is not not Available-for-sale marketable securities are classified as marketable securities, current or marketable securities, non-current depending on the contractual maturity date of the individual available-for-sale security.	Marketable securities Marketable securities consist of investments in US Treasury securities. Management determines the appropriate classification of these securities at the time they are acquired and evaluates the appropriateness of such classifications at each balance sheet date. We classify investments as available-for-sale pursuant to Financial Accounting Standards Board (“FASB”) Accounting Standard Codification (“ASC”) 320, no December 31, 2018 2017. no December 31, 2018 2017. We review investments for other-than-temporary impairment whenever the fair value of an investment is less than the amortized cost and evidence indicates that an investment’s carrying amount is not not Available-for-sale marketable securities are classified as marketable securities, current or marketable securities, non-current depending on the contractual maturity date of the individual available-for-sale security.
Fair Value of Financial Instruments, Policy [Policy Text Block]		Fair value of financial instruments Our financial instruments consist principally of cash and cash equivalents and restricted cash. The fair values of our cash equivalents are based on quoted market prices. The carrying amount of cash equivalents is equal to their respective fair values at December 31, 2018 2017,
Property, Plant and Equipment, Policy [Policy Text Block]		Property and equipment Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets (generally three ten
Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]		Restricted cash Restricted cash consists principally of a $140,000 May 26, 2004 $31,000 see, 18
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]		Long-lived assets Our long-lived assets, primarily consisting of intangible assets, are reviewed for impairment when events or changes in circumstances indicate the carrying amount of an asset may not No December 31, 2018 2017 no not
Collaborative Arrangement, Accounting Policy [Policy Text Block]		Collaborative arrangements We account for collaborative arrangements in accordance with applicable accounting guidance provided in ASC Topic 808, Collaborative Arrangements See, 16
Restructured Debt Liability, Contingent Milestone Payment, Policy [Policy Text Block]	Restructured D ebt L iability – Co ntingent M ilestone P ayment In conjunction with the November 2017 s ee, 8 $15 October 27, 2017 ( not	Restructured debt liability – contingent milestone payment In conjunction with the November 2017 see, 13 $15 October 27, 2017 ( not
Revenue [Policy Text Block]		Deferred revenue Deferred revenue represents amounts received prior to satisfying the revenue recognition criteria ( see 12 not 12 Deferred revenue primarily consists of amounts related to an upfront license fee received in July 2017 see 16
Revenue from Contract with Customer [Policy Text Block]		Revenue recognition Effective January 1, 2018, 606, 606, In accordance with ASC Topic 606, 606, five (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. We only apply the five 606, We have concluded that our government grants are not 606 not 958 605, Not not In the absence of applicable guidance under US GAAP, effective January 1, 2018, We believe this policy is consistent with the overarching premise in ASC Topic 606, no 606. 606. Prior to January 1, 2018, not no
Research and Development Expense, Policy [Policy Text Block]	Research and D evelopment We account for research and development expense by the following categories: (a) product development and manufacturing, (b) clinical medical and regulatory operations, and (c) direct preclinical and clinical development programs. Research and development expense includes personnel, facilities, manufacturing and quality operations, pharmaceutical and device development, research, clinical, regulatory, other preclinical and clinical activities and medical affairs. Research and development costs are charged to operations as incurred in accordance with ASC Topic 730, Research and Development	Research and development We account for research and development expense by the following categories: (a) product development and manufacturing, (b) medical and regulatory operations, and (c) direct preclinical and clinical development programs. Research and development expense includes personnel, facilities, manufacturing and quality operations, pharmaceutical and device development, research, clinical, regulatory, other preclinical and clinical activities and medical affairs. Research and development costs are charged to operations as incurred in accordance with Accounting Standards Codification (ASC) Topic 730, Research and Development
Share-based Payment Arrangement [Policy Text Block]		Stock-based compensation Stock-based compensation is accounted for under the fair value recognition provisions of ASC Topic 718, Stock Compensation 718 See 15
Derivatives, Policy [Policy Text Block]		Warrant accounting We account for common stock warrants in accordance with applicable accounting guidance provided in ASC Topic 815, Derivatives and Hedging – Contracts in Entity’s Own Equity 815
Income Tax, Policy [Policy Text Block]	Income T axes We account for income taxes in accordance with ASC Topic 740, Accounting for Income Taxes We use a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Because we have never realized a profit, management has fully reserved the net deferred tax asset since realization is not	Income taxes We account for income taxes in accordance with ASC Topic 740, We use a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Because we have never realized a profit, management has fully reserved the net deferred tax asset since realization is not
Stockholders' Equity Note, Convertible Preferred Stock, Beneficial Conversion Feature, Policy [Policy Text Block]		Beneficial Conversion Feature A beneficial conversion feature arises when a debt or equity security is issued with an embedded conversion option that is beneficial to the investor (or in the money) at inception due to the conversion option having an effective conversion price that is less than the fair value of the underlying stock at the commitment date. Preferred Stock The issuance of Series A Convertible Preferred Stock (Preferred Shares) in the first 2017 14 $3.6 one first 2017. An additional discount to the Preferred Shares of $4.5 December 31, 2018 December 31, 2017, $1.7 $2.8 December 31, 2018, no Convertible Note The issuance on July 2, 2018 $1.5 $1.5 $0.4 $0.4 $1.5 see 11 December 27, 2018, $1.5 $0.4 $5.11 $4.00, 375,000
Earnings Per Share, Policy [Policy Text Block]	Net L oss per C ommon S hare Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding for the period. Diluted net loss per common share is computed by giving effect to all potentially dilutive securities outstanding for the period. As of September 30, 2019 2018, 15.6 1.3 three nine September 30, 2019 2018,	Net loss per common share Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding for the period. Diluted net loss per common share is computed by giving effect to all potentially dilutive securities outstanding for the period. For the years ended December 31, 2018 2017, 14.4 1.0 December 31, 2018 2017, We do not
Concentration of Suppliers [Policy Text Block]		Concentration of Suppliers We currently obtain the active pharmaceutical ingredients (APIs) of our KL4 third KL4 one
Segment Reporting, Policy [Policy Text Block]		Business segments We currently operate in one one not
New Accounting Pronouncements, Policy [Policy Text Block]	Recently A dopted A ccounting S tandards In February 2016, No. 2016 02, Leases 2016 02 2016 02 842 840, Leases 842 2018. January 1, 2019 not not January 1, 2019. 840 ASC 842 not 12 not The adoption of this standard resulted in the recognition of operating lease liabilities and related right-of-use assets on our condensed consolidated balance sheets of $2.2 $2.0 842 $72,000 $139,000 not 10 In January 2017, No. 2017 04, 350 second December 15, 2019 January 1, 2019 December 31, 2019. Recently Issued Accounting Standards In August 2018, No. 2018 13, 820 2018 13 820. no 1 2 3 3 3 2018 13 December 15, 2019. 2018 13	Recent Accounting Pronouncements Recently Adopted Accounting Standards In May 2014, 2014 09, Revenue from Contracts with Customers (Topic 606 606 2014 09, January 1, 2018 June 2017, 2014 09 no no See, 16 In May 2017, 2017 09, Compensation—Stock Compensation (Topic 718 December 31, 2018 2017 09 January 1, 2018 not 2018 In August 2016, 2016 15, Statement of Cash Flows (Topic 230 eight one December 31, 2018 2016 15 January 1, 2018 not 2018 In January 2017, 2017 01, Business Combinations (Topic 805 first not not December 31, 2018 2017 01 January 1, 2018 not 2018 Recent Accounting Pronouncements In February 2016, 2016 02, Leases 842 January 1, 2019. not In January 2017, 2017 04, Intangibles - Goodwill and Other: Simplifying the Test for Goodwill Impairment 2017 04 second two not 2017 04 December 15, 2019; 2017 04 not
Lessee, Leases [Policy Text Block]	Leases Effective January 1, 2019, 842, Leases 842 not 840, Leases At the inception of an arrangement, we determine whether an arrangement is, or contains, a lease based on the unique facts and circumstances present in the arrangement. An arrangement is, or contains, a lease if the arrangement conveys the right to control the use of an identified asset for a period of time in exchange for consideration. Leases with a term greater than one not 12 not Operating lease liabilities and their corresponding operating lease right-of-use assets are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may not 842,

Note 3 - Business Combination (

Note 3 - Business Combination (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Business Acquisitions, by Acquisition [Table Text Block]	(in thousands) Cash and cash equivalents $ 193 Restricted cash 31 Prepaid expenses and other current assets 387 Property and equipment, net 76 Intangible assets 77,090 Total identifiable assets acquired $ 77,777 Current liabilities $ (2,590 ) Loan payable, current (3,453 ) Loan payable, non current (4,491 ) Deferred tax liabilities, noncurrent (15,418 ) Other liabilities, noncurrent (7 ) Net identifiable assets acquired 51,818 Goodwill 15,682 Net assets acquired $ 67,500
Business Acquisition, Pro Forma Information [Table Text Block]	Year Ended December 31, (in thousands, except per share data) 2018 2017 Pro forma net loss attributable to common shareholders $ (38,082 ) $ (34,616 ) Pro forma EPS - basic and diluted $ (1.20 ) $ (1.19 )
Warrants Issued for CVie Acquisition [Member]
Notes Tables
Schedule of Assumptions Used for Warrant Valution [Table Text Block]	Significant Input Assumptions of Warrant Valuation Historical volatility 116 % Expected term (in years) 2.5 Risk-free interest rate 2.62 %

Note 5 - Accounting Policies _2

Note 5 - Accounting Policies and Recent Accounting Pronouncements (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Notes Tables
Schedule of Indefinite-Lived Intangible Assets [Table Text Block]	(in thousands) Carrying Value Istaroxime drug candidate $ 22,340 Rostafuroxin drug candidate 54,750 Total $ 77,090	(in thousands) Estimated Fair Value Istaroxime drug candidate $ 22,340 Rostafuroxin drug candidate 54,750 Total $ 77,090

Note 6 - License Revenue with_2

Note 6 - License Revenue with Affiliate (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Notes Tables
Disaggregation of Revenue [Table Text Block]	Three Months Ended Nine Months Ended (in thousands) 2019 2018 2019 2018 License revenue with affiliate $ - $ 159 $ 198 $ 719	Year Ended December 31, (in thousands) 2018 2017 License revenue with affiliate $ 1,023 $ 102

Note 7 - Fair Value Measureme_2

Note 7 - Fair Value Measurements (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Notes Tables
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	Fair Value Fair value measurement using September 30, (in thousands) 2019 Level 1 Level 2 Level 3 Assets: Cash and cash equivalents $ 4,437 $ 4,437 $ - $ - U.S. Treasury notes - - - - Certificate of deposit 154 154 - - Total Assets $ 4,591 $ 4,591 $ - $ - Fair Value Fair value measurement using December 31, (in thousands) 2018 Level 1 Level 2 Level 3 Assets: Cash and cash equivalents $ 5,234 $ 5,234 $ - $ - U.S. Treasury notes 19,912 19,912 - - Certificate of deposit 171 171 - - Total Assets $ 25,317 $ 25,317 $ - $ -	Fair Value Fair value measurement using December 31, (in thousands) 2018 Level 1 Level 2 Level 3 Assets: Cash and cash equivalents $ 5,234 $ 5,234 $ - $ - U.S. Treasury notes 19,912 $ 19,912 Certificate of deposit 171 171 - - Total Assets $ 25,317 $ 25,317 $ - $ - Fair Value Fair value measurement using December 31, (in thousands) 2017 Level 1 Level 2 Level 3 Assets: Cash and cash equivalents $ 1,815 $ 1,815 $ - $ - Certificate of deposit 225 225 - - Total Assets $ 2,040 $ 2,040 $ - $ -

Note 8 - Property and Equipme_2

Note 8 - Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Property, Plant and Equipment [Table Text Block]	December 31, (in thousands) 2018 2017 Manufacturing, laboratory & office equipment $ 4,359 $ 4,965 Furniture & fixtures 390 615 Leasehold improvements 2,469 2,458 Subtotal 7,218 8,038 Accumulated depreciation and amortization (6,416 ) (7,153 ) Property and equipment, net $ 802 $ 885

Note 9 - Collaboration and De_2

Note 9 - Collaboration and Device Development Payable (Tables)	12 Months Ended
	Dec. 31, 2018
Series E Warrants [Member]
Notes Tables
Schedule of Assumptions Used for Warrant Valution [Table Text Block]	Significant Input Assumptions of Warrant Valuation Historical volatility 103 % Expected term (in years) 5 Risk-free interest rate 2.70 %

Note 10 - Accrued Expenses (Tab

Note 10 - Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	December 31, (in thousands) 2018 2017 Professional fees $ 2,473 $ 412 Research and development 2,361 1,778 Salaries, bonus & benefits 815 1,008 Manufacturing operations 212 537 Other 604 399 Total accrued expenses $ 6,465 $ 4,134

Note 12 - Convertible Note Pa_2

Note 12 - Convertible Note Payable (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Notes Tables
Convertible Note Interest Expense [Table Text Block]	Year Ended (in thousands) 2018 Non-cash amortization of debt discounts $ 833 Cash interest expense 106 Total convertible note interest expense $ 939
Series D Warrants [Member]
Notes Tables
Schedule of Assumptions Used for Warrant Valution [Table Text Block]		Significant Input Assumptions of Warrant Valuation Historical volatility 103 % Expected term (in years) 5 Risk-free interest rate 2.75 %

Note 13 - Restructured Debt L_2

Note 13 - Restructured Debt Liability (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Notes Tables
Schedule of Long-term Debt Instruments [Table Text Block]	September 30, December 31, (in thousands) 2019 2018 Restructured debt liability - contingent milestone payments $ 15,000 $ 15,000	December 31, December 31, (in thousands) 2018 2017 Restructured debt liability - contingent milestone payments $ 15,000 $ 15,000

Note 14 - Stockholders' Equity

Note 14 - Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Common Shares Reserved for Future Issuance, Warrants [Table Text Block]	December 31, Expiration (in thousands, except price per share data) 2018 2017 Exercise Price Date Investors - Aerosurf 2,963 - $ - 02/14/24 Investors - December 2018 financing - long-term 3,889 - $ 4.05 12/04/23 Investors - December 2018 financing - short-term 2,004 - $ 3.68 06/24/20 Battelle - 2018 payables restructuring agreement (1) 75 - $ 6.50 12/07/23 Panacea Venture Management Company Ltd. 188 - $ 4.00 07/02/23 LPH II Investments Limited 135 - $ 5.52 04/04/25 Investors - February 2017 financing 352 352 $ 27.40 02/15/24 Investors - July 2015 financing 240 240 $ 196.00 07/22/22 Battelle - 2014 collaboration agreement (1) 4 4 $ 1,400.00 10/10/24 Total 9,850 596

Note 15 - Stock Options and S_2

Note 15 - Stock Options and Stock-based Employee Compensation (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Notes Tables
Schedule of Share Based Compensation Arrangement by Stock Options and Restricted Stock Units Outstanding and Available for Future Issuance [Table Text Block]		<table style="margin-right: 15%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31,</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;">(in thousands)</div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Stock Options and RSUs Outstanding</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 59.9%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">2011 Plan</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,558</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">263</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Non-Plan</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Total Outstanding</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,568</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">273</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Available for Future Grants under 2011 Plan</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,453</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,623</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> </table></div>" id="sjs-C4">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt">&lt;table style="margin-right: 15%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> &lt;tr style="vertical-align: bottom;"> &lt;td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&lt;/td> &lt;td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&lt;/td> &lt;td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&lt;div style="display: inline; font-weight: bold;">&lt;div style="display: inline; font-weight: bold;">December 31,&lt;/div>&lt;/div>&lt;/div> &lt;/td> &lt;td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;&lt;/td> &lt;/tr> &lt;tr style="vertical-align: bottom;"> &lt;td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&lt;div style="display: inline; font-style: italic;">(in thousands)&lt;/div>&lt;/div> &lt;/td> &lt;td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&lt;/td> &lt;td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&lt;div style="display: inline; font-weight: bold;">&lt;div style="display: inline; font-weight: bold;">2018&lt;/div>&lt;/div>&lt;/div> &lt;/td> &lt;td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;&lt;/td> &lt;td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&lt;/td> &lt;td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&lt;div style="display: inline; font-weight: bold;">&lt;div style="display: inline; font-weight: bold;">2017&lt;/div>&lt;/div>&lt;/div> &lt;/td> &lt;td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;&lt;/td> &lt;/tr> &lt;tr style="vertical-align: bottom;"> &lt;td>&nbsp;&lt;/td> &lt;td>&nbsp;&lt;/td> &lt;td>&nbsp;&lt;/td> &lt;td>&nbsp;&lt;/td> &lt;td>&nbsp;&lt;/td> &lt;td>&nbsp;&lt;/td> &lt;td>&nbsp;&lt;/td> &lt;td>&nbsp;&lt;/td> &lt;td>&nbsp;&lt;/td> &lt;/tr> &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> &lt;td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Stock Options and RSUs Outstanding&lt;/div> &lt;/td> &lt;td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&lt;/td> &lt;td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&lt;/td> &lt;td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&lt;/td> &lt;td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&lt;/td> &lt;td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&lt;/td> &lt;td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&lt;/td> &lt;td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&lt;/td> &lt;td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&lt;/td> &lt;/tr> &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> &lt;td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 59.9%;"> &lt;div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">2011 Plan&lt;/div> &lt;/td> &lt;td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&lt;/td> &lt;td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&lt;/td> &lt;td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,558&lt;/div>&lt;/td> &lt;td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;&lt;/td> &lt;td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&lt;/td> &lt;td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&lt;/td> &lt;td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">263&lt;/div>&lt;/td> &lt;td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;&lt;/td> &lt;/tr> &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> &lt;td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> &lt;div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Non-Plan&lt;/div> &lt;/td> &lt;td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;&lt;/td> &lt;td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;&lt;/td> &lt;td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10&lt;/div>&lt;/td> &lt;td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">&nbsp;&lt;/td> &lt;td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;&lt;/td> &lt;td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;&lt;/td> &lt;td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10&lt;/div>&lt;/td> &lt;td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">&nbsp;&lt;/td> &lt;/tr> &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> &lt;td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> &lt;div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Total Outstanding&lt;/div> &lt;/td> &lt;td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&lt;/td> &lt;td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;&lt;/td> &lt;td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,568&lt;/div>&lt;/td> &lt;td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap">&nbsp;&lt;/td> &lt;td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&lt;/td> &lt;td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;&lt;/td> &lt;td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">273&lt;/div>&lt;/td> &lt;td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap">&nbsp;&lt;/td> &lt;/tr> &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> &lt;td>&nbsp;&lt;/td> &lt;td>&nbsp;&lt;/td> &lt;td>&nbsp;&lt;/td> &lt;td>&nbsp;&lt;/td> &lt;td>&nbsp;&lt;/td> &lt;td>&nbsp;&lt;/td> &lt;td>&nbsp;&lt;/td> &lt;td>&nbsp;&lt;/td> &lt;td>&nbsp;&lt;/td> &lt;/tr> &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> &lt;td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Available for Future Grants under 2011 Plan&lt;/div> &lt;/td> &lt;td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&lt;/td> &lt;td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;&lt;/td> &lt;td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,453&lt;/div>&lt;/td> &lt;td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap">&nbsp;&lt;/td> &lt;td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&lt;/td> &lt;td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;&lt;/td> &lt;td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,623&lt;/div>&lt;/td> &lt;td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap">&nbsp;&lt;/td> &lt;/tr> &lt;/table>&lt;/div>
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]	(in thousands, except for weighted-average data) Stock Options Shares Weighted- Weighted- Outstanding at January 1, 2019 4,417 $ 6.73 Granted 1,144 4.20 Forfeited or expired (5 ) 467.57 Outstanding at September 30, 2019 5,556 $ 5.80 9.2 Vested and exercisable at September 30, 2019 70 $ 128.45 6.3 Vested and expected to vest at September 30, 2019 5,245 $ 5.79 9.2	Weighted- Weighted- Average (in thousands, except for weighted-average data) Average Remaining Stock Options Shares Exercise Contractual Outstanding at January 1, 2018 84 $ 163.20 Granted 4,337 4.22 Forfeited or expired (4 ) 617.75 Outstanding at December 31, 2018 4,417 $ 6.73 9.9 Vested and exercisable at December 31, 2018 63 $ 171.87 6.5 Vested and expected to vest at December 31, 2018 4,243 $ 6.78 9.9
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]	(in thousands, except for weighted-average data) Restricted Stock Units Shares Weighted- Unvested at January 1, 2019 151 $ 4.29 Awarded 249 3.95 Vested (95 ) 3.95 Cancelled (144 ) 4.33 Unvested at September 30, 2019 161 $ 4.04	(in thousands, except for weighted-average data) Restricted Stock Units Shares Weighted- Unvested at January 1, 2018 190 $ 4.33 Awarded 56 4.22 Vested (95 ) 4.33 Unvested at December 31, 2018 151 $ 4.29
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three Months Ended Nine Months Ended (in thousands) 2019 2018 2019 2018 Research and development $ 574 $ 29 $ 1,613 $ 169 General and administrative 1,365 116 3,595 534 Total $ 1,939 $ 145 $ 5,208 $ 703	Year Ended (in thousands) 2018 2017 Research and development $ 232 $ 837 Selling, general and administrative 723 724 Total $ 955 $ 1,561
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Nine Months Ended 2019 Weighted average expected volatility 95% Weighted average expected term (in years) 6.6 Weighted average risk-free interest rate 2.6% Expected dividends -	Year Ended 2018 2017 Weighted average expected volatility 93% 79% Weighted average expected term (in years) 7.0 6.6 Weighted average risk-free interest rate 2.7% 2.2% Expected dividends - -

Note 20 - Income Taxes (Tables)

Note 20 - Income Taxes (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Notes Tables
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	December 31, (in thousands) 2018 2017 Income tax benefit, statutory rates $ (4,312 ) $ (6,272 ) State taxes on income, net of federal benefit (535 ) (398 ) Impact of tax reform 5 71,151 Research and development tax credit (351 ) (797 ) Foreign rate differential 24 - Employee related 2,875 953 Interest related 186 (147 ) Income tax expense / (benefit), statutory rates (2,108 ) 64,490 Valuation allowance 2,108 (64,490 ) Income tax benefit, net $ - $ -
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]		December 31, (in thousands) 2018 2017 Long-term deferred assets: Net operating loss carryforwards (federal and state) $ 176,759 $ 168,263 Research and development tax credit 16,718 16,813 Compensation expense on stock 1,121 1,191 Charitable contribution carryforward - 5 Other accrued 1,016 2,547 Deferred revenue 57 317 Depreciation 309 297 Total long-term deferred tax assets 195,980 189,433 Long-term deferred liabilities: IPR&D (15,476 ) - Total long-term deferred tax liabilities (15,476 ) - Valuation allowance (195,980 ) (189,433 ) Deferred tax liabilities, net $ (15,476 ) $ -

Note 21 - Selected Quarterly _2

Note 21 - Selected Quarterly Financial Data (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Quarterly Financial Information [Table Text Block]	2018 Quarters Ended: (in thousands, except per share data) Mar. 31 June 30 Sept. 30 Dec. 31 Total Year Revenues: Grant revenue $ - $ 695 $ 70 $ - $ 765 License revenue with affiliate 204 356 159 304 1,023 Total revenues 204 1,051 229 304 1,788 Expenses: Research and development 3,118 2,879 2,197 2,368 10,562 Selling, general and administrative 1,926 1,208 1,500 2,787 7,421 Total expenses 5,044 4,087 3,697 5,155 17,983 Operating loss (4,840 ) (3,036 ) (3,468 ) (4,851 ) (16,195 ) Other income / (expense), net 328 (16 ) (459 ) (4,191 ) (4,338 ) Net (loss) / income $ (4,512 ) $ (3,052 ) $ (3,927 ) $ (9,042 ) $ (20,533 ) AEROSURF warrant dividend - - - (12,505 ) (12,505 ) Deemed dividend on preferred stock - - - (1,718 ) (1,718 ) Net (loss) / income attributable to common shareholders $ (4,512 ) $ (3,052 ) $ (3,927 ) $ (23,265 ) $ (34,756 ) Net (loss) / income per common share - basic $ (1.40 ) $ (0.81 ) $ (1.04 ) $ (3.24 ) $ (7.74 ) Net (loss) / income per common share - diluted $ (1.40 ) $ (0.81 ) $ (1.04 ) $ (3.24 ) $ (7.74 ) Weighted average number of common shares outstanding - basic 3,227 3,751 3,769 7,191 4,493 Weighted average number of common shares outstanding - diluted 3,227 3,751 3,769 7,191 4,493 2017 Quarters Ended: (in thousands, except per share data) Mar. 31 June 30 Sept. 30 Dec. 31 Total Year Revenues: Grant revenue $ 219 $ 1,147 $ 17 $ - $ 1,383 License revenue with affiliate - - - 102 102 Total revenues 219 1,147 17 102 1,485 Expenses: Research and development 6,413 5,483 3,062 2,418 17,376 Selling, general and administrative 1,922 1,804 1,749 1,182 6,657 Total expenses 8,335 7,287 4,811 3,600 24,033 Operating loss (8,116 ) (6,140 ) (4,794 ) (3,498 ) (22,548 ) Other income / (expense), net (608 ) (612 ) (649 ) 5,971 4,102 Net (loss) / income $ (8,724 ) $ (6,752 ) $ (5,443 ) $ 2,473 $ (18,446 ) Deemed dividend on preferred stock (3,604 ) (532 ) (2,234 ) - (6,370 ) Net (loss) / income attributable to common shareholders $ (12,328 ) $ (7,284 ) $ (7,677 ) $ 2,473 $ (24,816 ) Net (loss) / income per common share - basic $ (27.40 ) $ (14.37 ) $ (10.53 ) $ 1.03 $ (24.14 ) Net (loss) / income per common share - diluted $ (27.40 ) $ (14.37 ) $ (10.53 ) $ 0.97 $ (24.14 ) Weighted average number of common shares outstanding - basic 450 507 729 2,405 1,028 Weighted average number of common shares outstanding - diluted 450 507 729 2,540 1,028

Note 4 - Summary of Significa_2

Note 4 - Summary of Significant Accounting Policies (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Notes Tables
Schedule of Indefinite-Lived Intangible Assets [Table Text Block]	(in thousands) Carrying Value Istaroxime drug candidate $ 22,340 Rostafuroxin drug candidate 54,750 Total $ 77,090	(in thousands) Estimated Fair Value Istaroxime drug candidate $ 22,340 Rostafuroxin drug candidate 54,750 Total $ 77,090

Note 5 - License Revenue with_2

Note 5 - License Revenue with Affiliate (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Notes Tables
Disaggregation of Revenue [Table Text Block]	Three Months Ended Nine Months Ended (in thousands) 2019 2018 2019 2018 License revenue with affiliate $ - $ 159 $ 198 $ 719	Year Ended December 31, (in thousands) 2018 2017 License revenue with affiliate $ 1,023 $ 102

Note 6 - Fair Value of Financ_2

Note 6 - Fair Value of Financial Instruments (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Notes Tables
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	Fair Value Fair value measurement using September 30, (in thousands) 2019 Level 1 Level 2 Level 3 Assets: Cash and cash equivalents $ 4,437 $ 4,437 $ - $ - U.S. Treasury notes - - - - Certificate of deposit 154 154 - - Total Assets $ 4,591 $ 4,591 $ - $ - Fair Value Fair value measurement using December 31, (in thousands) 2018 Level 1 Level 2 Level 3 Assets: Cash and cash equivalents $ 5,234 $ 5,234 $ - $ - U.S. Treasury notes 19,912 19,912 - - Certificate of deposit 171 171 - - Total Assets $ 25,317 $ 25,317 $ - $ -	Fair Value Fair value measurement using December 31, (in thousands) 2018 Level 1 Level 2 Level 3 Assets: Cash and cash equivalents $ 5,234 $ 5,234 $ - $ - U.S. Treasury notes 19,912 $ 19,912 Certificate of deposit 171 171 - - Total Assets $ 25,317 $ 25,317 $ - $ - Fair Value Fair value measurement using December 31, (in thousands) 2017 Level 1 Level 2 Level 3 Assets: Cash and cash equivalents $ 1,815 $ 1,815 $ - $ - Certificate of deposit 225 225 - - Total Assets $ 2,040 $ 2,040 $ - $ -

Note 8 - Restructured Debt Li_2

Note 8 - Restructured Debt Liability (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Notes Tables
Schedule of Long-term Debt Instruments [Table Text Block]	September 30, December 31, (in thousands) 2019 2018 Restructured debt liability - contingent milestone payments $ 15,000 $ 15,000	December 31, December 31, (in thousands) 2018 2017 Restructured debt liability - contingent milestone payments $ 15,000 $ 15,000

Note 9 - Stock Options and St_2

Note 9 - Stock Options and Stock-based Employee Compensation (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Notes Tables
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]	(in thousands, except for weighted-average data) Stock Options Shares Weighted- Weighted- Outstanding at January 1, 2019 4,417 $ 6.73 Granted 1,144 4.20 Forfeited or expired (5 ) 467.57 Outstanding at September 30, 2019 5,556 $ 5.80 9.2 Vested and exercisable at September 30, 2019 70 $ 128.45 6.3 Vested and expected to vest at September 30, 2019 5,245 $ 5.79 9.2	Weighted- Weighted- Average (in thousands, except for weighted-average data) Average Remaining Stock Options Shares Exercise Contractual Outstanding at January 1, 2018 84 $ 163.20 Granted 4,337 4.22 Forfeited or expired (4 ) 617.75 Outstanding at December 31, 2018 4,417 $ 6.73 9.9 Vested and exercisable at December 31, 2018 63 $ 171.87 6.5 Vested and expected to vest at December 31, 2018 4,243 $ 6.78 9.9
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]	(in thousands, except for weighted-average data) Restricted Stock Units Shares Weighted- Unvested at January 1, 2019 151 $ 4.29 Awarded 249 3.95 Vested (95 ) 3.95 Cancelled (144 ) 4.33 Unvested at September 30, 2019 161 $ 4.04	(in thousands, except for weighted-average data) Restricted Stock Units Shares Weighted- Unvested at January 1, 2018 190 $ 4.33 Awarded 56 4.22 Vested (95 ) 4.33 Unvested at December 31, 2018 151 $ 4.29
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Nine Months Ended 2019 Weighted average expected volatility 95% Weighted average expected term (in years) 6.6 Weighted average risk-free interest rate 2.6% Expected dividends -	Year Ended 2018 2017 Weighted average expected volatility 93% 79% Weighted average expected term (in years) 7.0 6.6 Weighted average risk-free interest rate 2.7% 2.2% Expected dividends - -
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three Months Ended Nine Months Ended (in thousands) 2019 2018 2019 2018 Research and development $ 574 $ 29 $ 1,613 $ 169 General and administrative 1,365 116 3,595 534 Total $ 1,939 $ 145 $ 5,208 $ 703	Year Ended (in thousands) 2018 2017 Research and development $ 232 $ 837 Selling, general and administrative 723 724 Total $ 955 $ 1,561

Note 10 - Leases (Tables)

Note 10 - Leases (Tables)	9 Months Ended
	Sep. 30, 2019
Notes Tables
Lease, Cost [Table Text Block]	Three Months Ended Nine Months Ended (in thousands) 2019 2019 Operating lease cost $ 212 $ 677 Variable lease cost 5 17 Total lease cost $ 217 $ 694 Other Information Operating cash flows used for operating leases $ 227 $ 721 Operating lease liabilities arising from obtaining right-of-use assets $ 232 $ 364 Weighted average remaining lease term (in years) 2.4 2.4 Weighted average incremental borrowing rate 9.00 % 9.00 %
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	As of (in thousands) 2019 2019 (excluding the nine months ended September 30, 2019) $ 230 2020 849 2021 638 2022 179 2023 23 Thereafter - Total lease payments 1,919 Less imputed interest (184 ) Total operating lease liabilities at September 30, 2019 1,735

Note 3 - Business Combination_2

Note 3 - Business Combination (Details Textual) - CVie Investments [Member] $ in Millions	Dec. 31, 2018USD ($)	Dec. 21, 2018USD ($)shares
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares | shares		16,256,060
Business Combination, Consideration Transferred, Total | $		$ 67.5
Indemnification Agreement, Shares Placed in Escrow | shares		984,000
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual | $	$ 0.5
In Process Research and Development [Member]
Indefinite-lived Intangible Assets Acquired | $		$ 77.1
Warrants Issued for CVie Acquisition [Member]
Business Combination, Ratio of Warrants Received for Each Share of Common Stock and Certain Warrants		0.6148
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares		2,963,167
Warrants and Rights Outstanding, Term		5 years
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right | shares		1
Warrants and Rights Outstanding | $		$ 12.5

Note 3 - Business Combination -

Note 3 - Business Combination - Warrant Valuation Assumptions (Details) - Warrants Issued for CVie Acquisition [Member]	Dec. 21, 2018
Measurement Input, Price Volatility [Member]
Measurement input	1.16
Measurement Input, Expected Term [Member]
Measurement input	2.5
Measurement Input, Risk Free Interest Rate [Member]
Measurement input	0.0262

Note 3 - Business Combination_3

Note 3 - Business Combination - Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018	Dec. 21, 2018	Dec. 31, 2017
Goodwill	$ (15,682)	$ (15,682)
CVie Investments [Member]
Cash and cash equivalents			$ 193
Restricted cash			31
Prepaid expenses and other current assets			387
Property and equipment, net			76
Intangible assets			77,090
Total identifiable assets acquired			77,777
Current liabilities			(2,590)
Loan payable, current			(3,453)
Loan payable, non current			(4,491)
Deferred tax liabilities, noncurrent			(15,418)
Other liabilities, noncurrent			(7)
Net identifiable assets acquired			51,818
Goodwill			(15,682)
Net assets acquired			$ 67,500

Note 3 - Business Combination_4

Note 3 - Business Combination - Pro Forma Information (Details) - CVie Investments [Member] - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Pro forma net loss attributable to common shareholders	$ (38,082)	$ (34,616)
Pro forma EPS - basic and diluted (in dollars per share)	$ (1.20)	$ (1.19)

Note 4 - Liquidity Risks and _2

Note 4 - Liquidity Risks and Management's Plans (Details Textual) - USD ($) $ in Thousands	Dec. 21, 2018	Dec. 31, 2018	Dec. 31, 2017	Sep. 30, 2019
Cash and Cash Equivalents, at Carrying Value, Ending Balance		$ 11,187	$ 1,815	$ 4,437
Debt Securities, Available-for-sale, Current, Total		13,959
Liabilities, Current, Total		20,633	11,760	16,278
Loans Payable, Current, Total		8,000		$ 7,800
Proceeds from Issuance of Private Placement	$ 39,000	$ 32,893	$ 14,860
Common Stock, Shares Authorized		120,000,000	120,000,000	120,000,000
Preferred Stock, Shares Authorized		5,000,000	5,000,000	5,000,000
Common Stock, Capital Shares Available for Issuance		72,000,000		72,000,000
Preferred Stock, Capital Shares Available for Issuance		5,000,000		5,000,000

Note 5 - Accounting Policies _3

Note 5 - Accounting Policies and Recent Accounting Pronouncements (Details Textual) $ / shares in Units, shares in Thousands	Dec. 27, 2018USD ($)$ / shares	Jul. 02, 2018USD ($)	Sep. 30, 2019USD ($)	Dec. 31, 2018USD ($)shares	Sep. 30, 2018USD ($)	Jun. 30, 2018USD ($)	Mar. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Sep. 30, 2017USD ($)	Jun. 30, 2017USD ($)	Mar. 31, 2017USD ($)	Sep. 30, 2019USD ($)shares	Sep. 30, 2018USD ($)shares	Dec. 31, 2018USD ($)shares	Dec. 31, 2017USD ($)shares	Dec. 26, 2018$ / shares	Feb. 28, 2018USD ($)	Dec. 01, 2017USD ($)	Nov. 01, 2017USD ($)
Foreign Currency Transaction Gain (Loss), before Tax, Total			$ 100,000		$ 0							$ 400,000	$ 0	$ 100,000	$ 0
Marketable Securities, Realized Gain (Loss), Total			14,000									75,000		0
Marketable Securities, Unrealized Gain (Loss), Total			(12,000)									0	$ 0	0
Asset Impairment Charges, Total														0
Liability for Contingent Milestone Payment, Noncurrent			15,000,000	$ 15,000,000				$ 15,000,000				$ 15,000,000		15,000,000	15,000,000
Preferred Stock Dividends, Income Statement Impact				$ 1,718,000					$ 2,234,000	$ 532,000	$ 3,604,000			$ 1,718,000	6,370,000
Preferred Stock, Discount on Shares								4,500,000							4,500,000
Preferred Stock, Shares Remaining to Be Converted | shares				0										0
Repayments of Convertible Debt														$ 1,500,000
Gain (Loss) on Extinguishment of Debt, Total														$ (3,345,000)
Number of Shares of Common Stock Potentially Issuable upon the Exercise of Stock Options and Warrants | shares												15,600	1,300	14,400	1,000
Number of Operating Segments														1
Conversion of Preferred Stock [Member]
Preferred Stock Dividends, Income Statement Impact														$ 1,700,000	$ 2,800,000
Panacea [Member] | Warrant Issued Related to Secured Convertible Promissory Note [Member]
Warrants and Rights Outstanding		$ 400,000
Panacea [Member] | Secured Convertible Promissory Note [Member]
Debt Instrument, Face Amount		1,500,000
Debt Instrument, Convertible, Beneficial Conversion Feature		$ 400,000
Repayments of Convertible Debt	$ 1,500,000
Gain (Loss) on Extinguishment of Debt, Total	$ 400,000
Share Price | $ / shares	$ 5.11
Debt Instrument, Convertible, Conversion Price | $ / shares	$ 4															$ 4
Debt Instrument, Convertible, Number of Equity Instruments	375,000
Deerfield Loan [Member]
Liability for Contingent Milestone Payment, Noncurrent			$ 15,000,000	$ 15,000,000				15,000,000				$ 15,000,000		15,000,000	15,000,000
Deerfield Loan [Member] | Exchange and Termination Agreement [Member] | Deerfield Management, L.P. [Member]
Liability for Contingent Milestone Payment, Noncurrent																		$ 15,000,000	$ 15,000,000
Headquarters [Member]
Security Deposit				140,000				$ 225,000						140,000	$ 225,000		$ 140,000
Offices, Taipei, Taiwan [Member]
Security Deposit				$ 31,000										$ 31,000
Minimum [Member]
Property, Plant and Equipment, Useful Life														3 years
Maximum [Member]
Property, Plant and Equipment, Useful Life														10 years

Note 5 - Accounting Policies _4

Note 5 - Accounting Policies and Recent Accounting Pronouncements - Intangible Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018	Dec. 31, 2017
Indefinite intangible asset	$ 77,090	$ 77,090
Istaroxime Drug Candidate [Member]
Indefinite intangible asset	22,340	22,340
Rostafuroxin Drug Candidate [Member]
Indefinite intangible asset	$ 54,750	$ 54,750

Note 6 - License Revenue with_3

Note 6 - License Revenue with Affiliate - Disaggregation of Revenue (Details) - USD ($) $ in Thousands

3 Months Ended

9 Months Ended

12 Months Ended

Sep. 30, 2019

Dec. 31, 2018

Sep. 30, 2018

Jun. 30, 2018

Mar. 31, 2018

Dec. 31, 2017

Sep. 30, 2017

Jun. 30, 2017

Mar. 31, 2017

Sep. 30, 2019

Sep. 30, 2018

Dec. 31, 2018

Dec. 31, 2017

License [Member]

License revenue with affiliate

$ 304

$ 159

$ 356

$ 204

$ 102

$ 198

$ 719

$ 1,023

$ 102

Note 7 - Fair Value Measureme_3

Note 7 - Fair Value Measurements - Assets and Liabilities Measured at Fair Value (Details) - Fair Value, Recurring [Member] - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018	Dec. 31, 2017
Cash and cash equivalents	$ 4,437	$ 5,234	$ 1,815
Total Assets	4,591	25,317	2,040
Certificates of Deposit [Member]
Certificate of deposit	154	171	225
US Treasury Securities [Member]
Cash and cash equivalents		19,912
Cash and cash equivalents		19,912
Fair Value, Inputs, Level 1 [Member]
Cash and cash equivalents	4,437	5,234	1,815
Total Assets	4,591	25,317	2,040
Fair Value, Inputs, Level 1 [Member] | Certificates of Deposit [Member]
Certificate of deposit	154	171	225
Fair Value, Inputs, Level 1 [Member] | US Treasury Securities [Member]
Cash and cash equivalents		19,912
Cash and cash equivalents		19,912
Fair Value, Inputs, Level 2 [Member]
Cash and cash equivalents
Total Assets
Fair Value, Inputs, Level 2 [Member] | Certificates of Deposit [Member]
Certificate of deposit
Fair Value, Inputs, Level 2 [Member] | US Treasury Securities [Member]
Cash and cash equivalents
Cash and cash equivalents
Fair Value, Inputs, Level 3 [Member]
Cash and cash equivalents
Total Assets
Fair Value, Inputs, Level 3 [Member] | Certificates of Deposit [Member]
Certificate of deposit
Fair Value, Inputs, Level 3 [Member] | US Treasury Securities [Member]
Cash and cash equivalents
Cash and cash equivalents

Note 8 - Property and Equipme_3

Note 8 - Property and Equipment (Details Textual) - USD ($) $ in Thousands	9 Months Ended		12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
Depreciation, Total	$ 178	$ 121	$ 160	$ 192

Note 8 - Property and Equipme_4

Note 8 - Property and Equipment - Property and Equipment (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018	Dec. 31, 2017
Property and equipment, gross		$ 7,218	$ 8,038
Accumulated depreciation and amortization		(6,416)	(7,153)
Property and equipment, net	$ 877	802	885
Manufacturing, Laboratory, and Office Equipment [Member]
Property and equipment, gross		4,359	4,965
Furniture and Fixtures [Member]
Property and equipment, gross		390	615
Leasehold Improvements [Member]
Property and equipment, gross		$ 2,469	$ 2,458

Note 9 - Collaboration and De_3

Note 9 - Collaboration and Device Development Payable (Details Textual)	Dec. 21, 2018USD ($)$ / sharesshares	Dec. 07, 2018USD ($)$ / sharesshares	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Sep. 30, 2019USD ($)	Dec. 06, 2018USD ($)
Collaboration and Device Development Payable, Current		$ 4,400,000	$ 2,576,000	$ 4,418,000	$ 1,873,000
Gain (Loss) on Extinguishment of Debt, Total			(3,345,000)
Conversion of Battelle Payables [Member]
Gain (Loss) on Extinguishment of Debt, Total	$ (500,000)
Debt Conversion, Converted Instrument, Amount	1,500,000
Debt Conversion, Original Debt, Amount	1,000,000
Private Placement [Member]
Debt Conversion, Original Debt, Amount	$ 6,000,000
Private Placement [Member] | Series F Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares	2,003,541
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 3.68
Warrants and Rights Outstanding, Term	1 year 180 days
Private Placement [Member] | Series G Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares	3,889,229
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 4.05
Warrants and Rights Outstanding, Term	5 years
Payment Restructuring of Battelle Payables [Member]
Collaboration and Device Development Payable, Interest Rate		6.00%
Collaboration and Device Development Payable, Repaid Payable Threshold to Qualify for Services on Credit		$ 3,000,000
Payments for Collaboration and Device Development Payable		972,281
Collaboration and Device Development Agreement, Aggregate Payments		$ 1,250,000
Collaboration and Device DevelopmentPayable, Number of Monthly Installments Payments Deferred		5
Collaboration and Device Development Payable, Periodic Payment, Total		$ 250,000
Royalty Guarantees, Commitments, Amount		$ 35,000,000				$ 25,000,000
Interest Payable, Current			$ 300,000
Payment Restructuring of Battelle Payables [Member] | Series E Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares		$ 6.50
Warrants and Rights Outstanding, Term		5 years
Common Stock Maximum Ownership Percentage For Warrant Exercise		9.99%
Payment Restructuring of Battelle Payables [Member] | Series E Warrants [Member] | Common Stock [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares		75,000
Payment Restructuring of Battelle Payables [Member] | Private Placement [Member]
Collaboration and Device Development Payable, Converted Payable Amount into Equity	$ 1,000,000
Sale of Stock, Number of Shares Issued in Transaction | shares	301,823
Sale of Stock, Price Per Share | $ / shares	$ 3.3132
Payment Restructuring of Battelle Payables [Member] | Private Placement [Member] | Series F Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 3.68
Warrants and Rights Outstanding, Term	1 year 180 days
Payment Restructuring of Battelle Payables [Member] | Private Placement [Member] | Series F Warrants [Member] | Common Stock [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares	51,310
Payment Restructuring of Battelle Payables [Member] | Private Placement [Member] | Series G Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 4.05
Warrants and Rights Outstanding, Term	5 years
Payment Restructuring of Battelle Payables [Member] | Private Placement [Member] | Series G Warrants [Member] | Common Stock [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares	99,602

Note 9 - Collaboration and De_4

Note 9 - Collaboration and Device Development Payable - Significant Input Assumptions of Warrant Valuation (Details) - Series E Warrants [Member]	Dec. 07, 2018
Measurement Input, Price Volatility [Member]
Measurement input	1.03
Measurement Input, Expected Term [Member]
Measurement input	5
Measurement Input, Risk Free Interest Rate [Member]
Measurement input	0.027

Note 10 - Accrued Expenses - Ac

Note 10 - Accrued Expenses - Accrued Expenses (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018	Dec. 31, 2017
Professional fees		$ 2,473	$ 412
Research and development		2,361	1,778
Salaries, bonus & benefits		815	1,008
Manufacturing operations		212	537
Other		604	399
Total accrued expenses	$ 5,235	$ 6,465	$ 4,134

Note 11 - Loan Payable (Details

Note 11 - Loan Payable (Details Textual) $ / shares in Units, $ in Millions	Dec. 27, 2018USD ($)	Dec. 21, 2018USD ($)$ / sharesshares	Mar. 31, 2018USD ($)	Jan. 31, 2018USD ($)	Sep. 30, 2017USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Sep. 30, 2019USD ($)	Dec. 31, 2018TWD ($)	Dec. 21, 2018TWD ($)shares	Dec. 05, 2018USD ($)	Nov. 19, 2018USD ($)	Nov. 16, 2018USD ($)	Nov. 02, 2018USD ($)	Oct. 19, 2018USD ($)	Sep. 27, 2018USD ($)	Sep. 12, 2018USD ($)	Aug. 29, 2018USD ($)	Aug. 14, 2018USD ($)	Sep. 30, 2017TWD ($)	Sep. 30, 2016USD ($)	Sep. 30, 2016TWD ($)
Gain (Loss) on Extinguishment of Debt, Total						$ (3,345,000)
Short-term Debt, Total						7,974,000		$ 7,782,000
Debt Payable to Lee's International [Member]
Debt Instrument, Interest Rate, Stated Percentage													4.00%
Debt Instrument, Face Amount													$ 3,500,000
Short-term Debt, Total								3,000,000
Long-term Debt, Current Maturities, Total						$ 3,500,000			$ 106.2
Debt Payable to Lee's International [Member] | Debt Maturing April 2019 [Member]
Debt Instrument, Face Amount													500,000
Debt Payable to Lee's International [Member] | Debt Maturing September 2019 [Member]
Debt Instrument, Face Amount													300,000
Debt Payable to Lee's International [Member] | Debt Maturing October 2019 [Member]
Debt Instrument, Face Amount													200,000
Debt Payable to Lee's International [Member] | Debt Maturing November 2019 [Member]
Debt Instrument, Face Amount													$ 2,500,000
CVie Investments [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Total		$ 2,590,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt		3,453,000
CVie Investments [Member] | Debt Payable to Lee's International [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt		3,500,000								$ 106.2
Private Placement [Member]
Debt Conversion, Original Debt, Amount		$ 6,000,000
Debt Conversion, Converted Instrument, Shares Issued | shares		1,810,938
Shares Issued, Price Per Share | $ / shares		$ 3.3132
Private Placement [Member] | Lee’s Pharmaceutical Holdings Limited [Member]
Debt Conversion, Original Debt, Amount		$ 6,000,000
Private Placement [Member] | Series F Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares		2,003,541								2,003,541
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares		$ 3.68
Warrants and Rights Outstanding, Term		1 year 180 days								1 year 180 days
Private Placement [Member] | Series F Warrants [Member] | Lee’s Pharmaceutical Holdings Limited [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares		307,859								307,859
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares		$ 3.68
Warrants and Rights Outstanding, Term		1 year 180 days								1 year 180 days
Private Placement [Member] | Series G Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares		3,889,229								3,889,229
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares		$ 4.05
Warrants and Rights Outstanding, Term		5 years								5 years
Private Placement [Member] | Series G Warrants [Member] | Lee’s Pharmaceutical Holdings Limited [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares		597,610								597,610
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares		$ 4.05
Warrants and Rights Outstanding, Term		5 years								5 years
LPH [Member]
Proceeds from Issuance of Debt			$ 1,000,000	$ 1,500,000
Debt Instrument, Interest Rate, Stated Percentage						6.00%			6.00%
Debt Instrument, Face Amount											$ 600,000	$ 350,000		$ 500,000	$ 430,000	$ 500,000	$ 500,000	$ 480,000	$ 300,000
Gain (Loss) on Extinguishment of Debt, Total		$ (3,200,000)
Common Stock and Warrants for Debt Settlement, Fair Value		9,200,000
Short-term Debt, Total		6,000,000
Repayments of Debt	$ 160,000
Interest Paid, Including Capitalized Interest, Operating and Investing Activities, Total	$ 182,000
LPH II [Member]
Debt Instrument Requirement For Minimum Amount Rise						$ 30,000,000
O-Bank Co., Ltd. [Member] | Revolving Credit Facility [Member]
Line of Credit Facility, Percent of Pledged Deposits Required					110.00%	110.00%			110.00%											110.00%
Line of Credit, Current						$ 4,500,000		$ 4,500,000	$ 138
O-Bank Co., Ltd. [Member] | Revolving Credit Facility [Member] | Taipei Interbank Offer Rate (TAIBOR) [Member]
Debt Instrument, Basis Spread on Variable Rate					0.91%	0.91%
O-Bank Co., Ltd. [Member] | Revolving Credit Facility [Member] | CVie Investments [Member]
Line of Credit Facility, Maximum Borrowing Capacity					$ 5,840,000															$ 180	$ 2,900,000	$ 90
O-Bank Co., Ltd. [Member] | CVie Investments [Member] | Revolving Credit Facility [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Total		$ 4,500,000	$ 4,500,000							$ 138

Note 12 - Convertible Note Pa_3

Note 12 - Convertible Note Payable (Details Textual)	Dec. 27, 2018USD ($)$ / shares	Jul. 23, 2018USD ($)	Jul. 02, 2018USD ($)$ / sharesshares	Sep. 30, 2019USD ($)	Sep. 30, 2018USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Dec. 26, 2018$ / shares
Proceeds from Convertible Debt					$ 1,500,000	$ 1,500,000
Repayments of Convertible Debt						1,500,000
Gain (Loss) on Extinguishment of Debt, Total						(3,345,000)
Panacea [Member] | Secured Convertible Promissory Note [Member]
Debt Instrument, Face Amount			$ 1,500,000
Debt Instrument, Convertible, Conversion Price | $ / shares	$ 4							$ 4
Debt Instrument, Convertible, Beneficial Conversion Feature			$ 400,000
Repayments of Convertible Debt	$ 1,500,000
Gain (Loss) on Extinguishment of Debt, Total	$ 400,000
Share Price | $ / shares	$ 5.11
Debt Instrument, Convertible, Number of Equity Instruments	375,000
Panacea [Member] | Series D Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares			187,500
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares			$ 4
Class of Warrant or Right, Vesting Period			180 days
Warrants and Rights Outstanding, Term			5 years
Common Stock Maximum Ownership Percentage For Warrant Exercise			9.99%
Panacea [Member] | Series D Warrants [Member] | Warrant [Member]
Derivative Liability, Total						400,000
Convertible Notes Payable [Member] | Panacea [Member]
Debt Instrument, Face Amount			$ 1,500,000
Proceeds from Convertible Debt		$ 500,000	$ 1,000,000
Debt Instrument, Interest Rate, Stated Percentage			15.00%
Debt Instrument, Convertible, Conversion Price | $ / shares			$ 4
Debt Instrument, Convertible, Beneficial Conversion Feature						$ 400,000

Note 12 - Convertible Note Pa_4

Note 12 - Convertible Note Payable - Significant Input Assumptions of Warrant Valuation (Details) - Series D Warrants [Member]	Dec. 31, 2018
Measurement Input, Price Volatility [Member]
Measurement input	1.03
Measurement Input, Expected Term [Member]
Measurement input	5
Measurement Input, Risk Free Interest Rate [Member]
Measurement input	0.0275

Note 12 - Convertible Note Pa_5

Note 12 - Convertible Note Payable - Convertible Note Interest Expense (Details) - Convertible Notes Payable [Member] $ in Thousands	12 Months Ended
	Dec. 31, 2018USD ($)
Non-cash amortization of debt discounts	$ 833
Cash interest expense	106
Total convertible note interest expense	$ 939

Note 13 - Restructured Debt L_3

Note 13 - Restructured Debt Liability (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	Nov. 01, 2017	Dec. 31, 2018	Dec. 31, 2017	Sep. 30, 2019
Repayments of Long-term Debt, Total			$ 2,500
Liability for Contingent Milestone Payment, Noncurrent		15,000	15,000	$ 15,000
Deerfield Loan [Member]
Liability for Contingent Milestone Payment, Noncurrent		$ 15,000	$ 15,000	$ 15,000
Deerfield Loan [Member] | Exchange and Termination Agreement [Member] | Deerfield Management, L.P. [Member]
Extinguishment of Debt, Amount	$ 25,000
Class of Warrant or Right, Number of Warrants Cancelled	25,000
Class of Warrant or Right, Exercise Price of Cancelled Warrants	$ 786.80
Repayments of Long-term Debt, Total	$ 2,500
Stock Issued During Period, Shares, Cancellation of Debt and Warrant Obligations	71,111
Stock Issued During Period, Shares, Cancellation of Debt and Warrant Obligations, Percentage of Fully-diluted Shares Outstanding	2.00%
Liability for Contingent Milestone Payment, Noncurrent	$ 15,000

Note 13 - Restructured Debt L_4

Note 13 - Restructured Debt Liability - Long-term Debt (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018	Dec. 31, 2017
Restructured debt liability - contingent milestone payments	$ 15,000	$ 15,000	$ 15,000
Deerfield Loan [Member]
Restructured debt liability - contingent milestone payments	$ 15,000	$ 15,000	$ 15,000

Note 14 - Stockholders' Equit_2

Note 14 - Stockholders' Equity (Details Textual) - USD ($)	Dec. 24, 2018	Dec. 21, 2018	Apr. 04, 2018	Nov. 01, 2017	Oct. 27, 2017	Oct. 25, 2017	Feb. 15, 2017	Feb. 11, 2013	Oct. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Sep. 30, 2019
Common Stock, Shares, Issued, Total										32,133,263	3,227,495	32,188,929
Proceeds from Issuance of Private Placement		$ 39,000,000								$ 32,893,000	$ 14,860,000
Preferred Stock, Par or Stated Value Per Share							$ 0.001			$ 0.001	$ 0.001	$ 0.001
Proceeds from Issuance of Common Stock											$ 1,036,000
Common Stock, Capital Shares Reserved for Future Issuance										9,850,000	596,000
The 2011 Long-term Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized	4,200,000					1,750,000					37,500
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant										1,453,000	1,623,000
The 401(k) Plan [Member]
Common Stock, Capital Shares Reserved for Future Issuance											807
LPH [Member] | Acquisition of Windtree [Member]
Business Combination, Consideration Transferred, Total				$ 10,000,000	$ 10,000,000
Business Acquisition, Shares Acquired, Number					2,311,604
Business Acquisition, Share Price					$ 4.326
Business Acquisition, Shares Acquired, Price Per Share, Percentage Premium					15.00%
Business Acquisition, Percentage of Voting Interests Acquired					73.00%
Business Combination, Consideration Transferred, Liabilities Cancelled					$ 3,900,000
Business Combination, Number of Individuals Acquirer May Appoint to the Acquiree's Board of Directors					2
Business Combination, Registration Rights Agreement, Maximum Rights Percentage in First 18 Months					25.00%
Battelle [Member] | Series A Preferred Stock [Member]
Preferred Stock, Convertible, Shares, Liquidity Preference Waived									1,095
Private Placement [Member]
Common Stock, Shares, Issued, Total		11,785,540
Share Price		$ 3.3132
Proceeds from Issuance of Private Placement		$ 39,000,000
Debt Conversion, Original Debt, Amount		$ 6,000,000
Shares Issued, Price Per Share		$ 3.3132
Private Placement [Member] | Series F Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		2,003,541
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 3.68
Warrants and Rights Outstanding, Term		1 year 180 days
Private Placement [Member] | Series G Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		3,889,229
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 4.05
Warrants and Rights Outstanding, Term		5 years
Private Placement [Member] | December 2018 Warrants [Member]
Common Stock Maximum Ownership Percentage For Warrant Exercise		9.99%
Private Placement [Member] | Series A Units [Member]
Stock Issued During Period, Shares, New Issues							7,049
Convertible Preferred Stock Units, Price Per Unit							$ 1,495
Gross Proceeds From Issuance Of Units							$ 10,500,000
Non-cash Consideration Received							$ 1,600,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right							1
Private Placement [Member] | Series A Warrant [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 27.40
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right							50
Class of Warrants May Not Exercise to Extent, Percentage							9.99%
Private Placement [Member] | Lee’s Pharmaceutical Holdings Limited [Member]
Debt Conversion, Original Debt, Amount		$ 6,000,000
Private Placement [Member] | Lee’s Pharmaceutical Holdings Limited [Member] | Series F Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		307,859
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 3.68
Warrants and Rights Outstanding, Term		1 year 180 days
Private Placement [Member] | Lee’s Pharmaceutical Holdings Limited [Member] | Series G Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		597,610
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 4.05
Warrants and Rights Outstanding, Term		5 years
Private Placement [Member] | Battelle [Member]
Debt Conversion, Original Debt, Amount		$ 1,000,000
Private Placement [Member] | LPH II [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			135,417
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 5.52
Warrants and Rights Outstanding, Term			7 years
Private Placement, Purchase Price of Common Stock and Warrants			$ 2,600,000
Shares Issued, Price Per Share			$ 4.80
Stock Issued During Period, Shares, New Issues			541,667
Class of Warrant or Right, Vesting Period			180 days
Registration Rights Agreement, Rights Percentage			25.00%
Stifel ATM Program [Member]
Stock Issued During Period, Shares, New Issues											42,357
Agency Agreement Period								3 years
Maximum Potential Common Stock Available for Issue, Value								$ 25,000,000
Percentage Sales Commission on Shares								3.00%
Proceeds from Issuance of Common Stock											$ 1,100,000
Proceeds from Issuance of Common Stock, Net											$ 1,000,000
The 401(k) Plan [Member]
Stock Issued During Period, Shares, New Issues											7,561
Defined Contribution Plan, Cost										$ 0	$ 100,000

Note 14 - Stockholders' Equit_3

Note 14 - Stockholders' Equity - Common Shares Reserved for Future Issuance (Details) - $ / shares shares in Thousands		12 Months Ended
		Dec. 31, 2018		Dec. 31, 2017
Common Stock, Capital Shares Reserved for Future Issuance		9,850		596
Investors - Aerosurf [Member]
Common Stock, Capital Shares Reserved for Future Issuance		2,963
Class of Warrant or Right, Exercise Price of Warrants or Rights
Expiration date		02/14/24
Investors - December 2018 Financing - Long-term [Member]
Common Stock, Capital Shares Reserved for Future Issuance		3,889
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 4.05
Expiration date		12/04/23
Investors - December 2018 Financing - Short-term [Member]
Common Stock, Capital Shares Reserved for Future Issuance		2,004
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 3.68
Expiration date		06/24/20
Battelle - 2018 Payables Restructuring Agreement [Member]
Common Stock, Capital Shares Reserved for Future Issuance		75	[1]
Class of Warrant or Right, Exercise Price of Warrants or Rights	[1]	$ 6.50
Expiration date	[1]	12/07/23
Panacea Venture Management Company Ltd. [Member]
Common Stock, Capital Shares Reserved for Future Issuance		188
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 4
Expiration date		07/02/23
LPH II Investments Limited [Member]
Common Stock, Capital Shares Reserved for Future Issuance		135
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 5.52
Expiration date		04/04/25
Investors - February 2017 Financing [Member]
Common Stock, Capital Shares Reserved for Future Issuance		352		352
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 27.40
Expiration date		02/15/24
Investors - July 2015 Financing [Member]
Common Stock, Capital Shares Reserved for Future Issuance		240		240
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 196
Expiration date		07/22/22
Battelle 2014 Collaboration Agreement [Member]
Common Stock, Capital Shares Reserved for Future Issuance	[1]	4		4
Class of Warrant or Right, Exercise Price of Warrants or Rights	[1]	$ 1,400
Expiration date	[1]	10/10/24
[1]	See, - Note 16 - Collaboration and Device Development Payment Restructuring, Licensing and Research Funding Agreements for further details on the Battelle collaboration agreement.

Note 15 - Stock Options and S_3

Note 15 - Stock Options and Stock-based Employee Compensation (Details Textual) - USD ($) $ / shares in Units, shares in Thousands	Feb. 01, 2016	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value											$ 3.39	$ 17.44
APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total		$ 1,938,000	$ 1,739,000	$ 1,530,000	$ 145,000	$ 140,000	$ 418,000			$ 1,000,000	$ 955,000	$ 1,600,000
Share-based Payment Arrangement, Expense		$ 1,939,000			$ 145,000			$ 5,208,000	$ 703,000		955,000	1,561,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value											600,000	$ 1,900,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total										13,900,000	$ 13,900,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition											2 years 328 days
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value								$ 3.95			$ 4.22	$ 4.33
Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value										$ 0	$ 0
Chief Executive Officer [Member] | Non-plan Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years
The 2011 Long-term Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized										6,100	6,100
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant										1,453	1,453	1,623
Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period												3 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period												10 years
Share-based Payment Arrangement, Expense												$ 400,000

Note 15 - Stock Options and S_4

Note 15 - Stock Options and Stock-based Employee Compensation - Stock Options and Restricted Stock Units (RSUs) Outstanding and Available for Future Issuance (Details) - shares shares in Thousands	Dec. 31, 2018	Dec. 31, 2017
2011 Plan (in shares)	4,568	273
The 2011 Long-term Incentive Plan [Member]
2011 Plan (in shares)	4,558	263
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	1,453	1,623
Non-Plan [Member]
2011 Plan (in shares)	10	10

Note 15 - Stock Options and S_5

Note 15 - Stock Options and Stock-based Employee Compensation - Summary of Stock Option Activity (Details) - $ / shares shares in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Shares Outstanding, Beginning Balance (in shares)	4,417	84
Weighted Average Exercise Price, Outstanding, at Beginning Period (in dollars per share)	$ 6.73	$ 163.20
Shares Granted (in shares)	1,144	4,337
Weighted Average Exercise Price, Granted (in dollars per share)	$ 4.20	$ 4.22
Shares Forfeited or Expired (in shares)	(5)	(4)
Weighted Average Exercise Price, Forfeited or Expired (in dollars per share)	$ 467.57	$ 617.75
Shares Outstanding, Ending Balance (in shares)	5,556	4,417
Weighted Average Exercise Price, Outstanding, at Ending Period (in dollars per share)	$ 5.80	$ 6.73
Weighted Average Remaining Contractual Life, Outstanding (Year)	9 years 73 days	9 years 328 days
Shares Vested and Exercisable (in shares)	70	63
Weighted Average Exercise Price, Vested and Exercisable (in dollars per share)	$ 128.45	$ 171.87
Weighted Average Remaining Contractual Life, Vested and Exercisable (Year)	6 years 109 days	6 years 182 days
Vested and expected to vest (in shares)	5,245	4,243
Weighted Average Exercise Price, Vested and Expected to Vest (in dollars per share)	$ 5.79	$ 6.78
Weighted Average Remaining Contractual Life, Vested and Expected to Vest (Year)	9 years 73 days	9 years 328 days

Note 15 - Stock Options and S_6

Note 15 - Stock Options and Stock-based Employee Compensation - Summary of Restricted Stock Units Activity (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares shares in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018	Dec. 31, 2017
Unvested, Beginning Balance (in shares)	151	190
Unvested, Beginning Balance (in dollars per share)	$ 4.29	$ 4.33
Awarded (in shares)	249	56
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 3.95	$ 4.22	$ 4.33
Vested (in shares)	(95)	(95)
Vested (in dollars per share)	$ 3.95	$ 4.33
Unvested, Ending Balance (in shares)	161	151	190
Unvested, Ending Balance (in dollars per share)	$ 4.04	$ 4.29	$ 4.33

Note 15 - Stock Options and S_7

Note 15 - Stock Options and Stock-based Employee Compensation - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
Share-based Payment Arrangement, Expense	$ 1,939	$ 145	$ 5,208	$ 703	$ 955	$ 1,561
Research and Development Expense [Member]
Share-based Payment Arrangement, Expense	$ 574	$ 29	$ 1,613	$ 169	232	837
Selling, General and Administrative Expenses [Member]
Share-based Payment Arrangement, Expense					$ 723	$ 724

Note 15 - Stock Options and S_8

Note 15 - Stock Options and Stock-based Employee Compensation - Stock Options Valuation Assumptions (Details)	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018	Dec. 31, 2017
Weighted average expected volatility	95.00%	93.00%	79.00%
Weighted average expected term (Year)	6 years 219 days	7 years	6 years 219 days
Weighted average risk-free interest rate	2.60%	2.70%	2.20%
Expected dividends

Note 16 - Collaboration, Lice_2

Note 16 - Collaboration, Licensing and Research Funding Agreements (Details Textual) € in Millions	Nov. 01, 2017USD ($)	Oct. 27, 2017USD ($)	Aug. 31, 2017USD ($)	Jun. 30, 2017USD ($)	Oct. 31, 2014USD ($)	Oct. 31, 2017USD ($)	Sep. 30, 2019USD ($)	Sep. 30, 2018USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2018EUR (€)	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2012USD ($)
Proceeds from Short-term Debt, Total								$ 4,280,000	$ 6,160,000		$ 3,900,000
LPH [Member] | Acquisition of Windtree [Member]
Business Combination, Consideration Transferred, Total	$ 10,000,000	$ 10,000,000
Maximum [Member] | Lee's [Member] | Lee's Loan to Support Operations [Member]
Proceeds from Short-term Debt, Total						$ 3,900,000
License Agreement With Lee’s [Member]
Proceeds from License Fees Received				$ 1,000,000					1,000,000
License Agreement, Contingent Receivable, Maximum			$ 35,800,000	$ 37,500,000
Fair Value of Royalties and Milestones Foregone									300,000
Revenue, Remaining Performance Obligation, Amount									1,300,000
Philip Morris USA Inc. - License Agreement [Member]
Payments for Royalties											300,000
Deferred Royalty Expense											300,000
Philip Morris Products S.A. - License Agreement [Member]
Payments for Royalties											$ 487,500
Deferred Royalty Expense									400,000			$ 187,500
Johnson and Johnson - License Agreement [Member]
Potential License Fee Payable									2,500,000
Payment of License Cost Subject to Regulatory Approval									$ 1,000,000				$ 500,000
Percent of Cash Upfront and Milestone Fees Payable to Esteve									10.00%
Maximum Aggregate Cash Upfront and Milestone Fees Payable to Esteve									$ 20,000,000
Universita Degli Studi Do Miano-Biocca [Member]
Payment of License Cost for New Compounds Modulating									100,000	€ 0.1
Payment of License Cost Upon Obtaining Marketing Authorization									1,700,000	€ 1.5
Payment of License Cost, Aggregation Fund									200,000
Battelle Applies [Member]
Maximum Royalty Paid on Completion of Activities Under the Agreement					$ 25,000,000				$ 35,000,000

Note 17 - Related Party Trans_2

Note 17 - Related Party Transactions (Details Textual) - USD ($) $ in Millions	1 Months Ended				12 Months Ended
	Dec. 31, 2018	Jul. 31, 2018	Apr. 30, 2018	Oct. 31, 2017	Dec. 31, 2018	Dec. 31, 2017
Affiliate of Lee’s [Member] | Share Purchase Agreement [Member]
Related Party Transaction, Amounts of Transaction				$ 10
Affiliate of Lee’s [Member] | Private Placement in a related Party Transaction [Member]
Related Party Transaction, Amounts of Transaction			$ 2.6
Affiliate of Lee’s [Member] | Converting Existing Loans Payable [Member]
Related Party Transaction, Amounts of Transaction	$ 6
Lee’s Pharmaceutical Holdings Limited [Member] | Bank Credit Facility is Guaranteed [Member]
Related Party Transaction, Amounts of Transaction					$ 4.5
Affiliate of Panacea [Member] | Secured Convertible Promissory Note [Member]
Related Party Transaction, Amounts of Transaction		$ 1.5
Rui Jin (HK) Consulting Management Company Limited, an affiliate of Panacea [Member]
Related Party Transaction, Shares Issued					114,415
Lee’s Pharmaceutical Holdings Limited [Member] | Windtree Therapeutics [Member]
Ownership Percentage	40.00%				40.00%	73.00%
Lee’s Pharmaceutical Holdings Limited [Member] | CVie Investment [Member]
Ownership Percentage	49.00%				49.00%
KPCB [Member] | Windtree Therapeutics [Member]
Ownership Percentage	14.00%				14.00%
KPCB [Member] | CVie [Member]
Ownership Percentage	27.00%				27.00%

Note 18 - Commitments (Details

Note 18 - Commitments (Details Textual)	Dec. 21, 2018USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Sep. 30, 2019USD ($)	Nov. 30, 2018USD ($)	Feb. 28, 2018USD ($)ft²	Apr. 30, 2016ft²
Operating Leases, Rent Expense, Net, Total		$ 800,000	$ 700,000
Eligible Transaction, Minimum Gross Proceeds from Financing					$ 30,000,000
Strategic and Retention Bonus, Maximum Bonus, Requirement, Eligible Transaction, Minimum Gross Proceeds					$ 45,000,000
Minimum Bonus Amount, Percentage of Maximum Bonus Amount					20.00%
Private Placement Financing, Value	$ 39,000,000
Eligible Participants, Total Bonus	$ 1,400,000
Eligible Participants, Bonus Installment		700,000
Forecast [Member]
Eligible Participants, Bonus Installment				$ 700,000
Headquarters [Member]
Area of Real Estate Property | ft²						21,189	30,506
Security Deposit		140,000	$ 225,000			$ 140,000
Operating Leases, Future Minimum Payments Due, Total		$ 2,100,000

Note 20 - Income Taxes (Details

Note 20 - Income Taxes (Details Textual) - USD ($) $ in Millions	Dec. 31, 2018	Dec. 31, 2017
Operating Loss Carryforwards, Total	$ 606.6	$ 590
State and Local Jurisdiction [Member]
Operating Loss Carryforwards, Total	584.8	567.7
State and Local Jurisdiction [Member] | Pennsylvania [Member]
Operating Loss Carryforwards, Total	570.2
Research Tax Credit Carryforward [Member]
Tax Credit Carryforward, Amount	$ 16.7	$ 16.8

Note 20 - Income Taxes - Income

Note 20 - Income Taxes - Income Tax Reconciliation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Income tax benefit, statutory rates	$ (4,312)	$ (6,272)
State taxes on income, net of federal benefit	(535)	(398)
Impact of tax reform	5	71,151
Research and development tax credit	(351)	(797)
Foreign rate differential	24
Employee related	2,875	953
Interest related	186	(147)
Income tax expense / (benefit), statutory rates	(2,108)	64,490
Valuation allowance	2,108	(64,490)
Income tax benefit, net

Note 20 - Income Taxes - Deferr

Note 20 - Income Taxes - Deferred Tax Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Net operating loss carryforwards (federal and state)	$ 176,759	$ 168,263
Research and development tax credit	16,718	16,813
Compensation expense on stock	1,121	1,191
Charitable contribution carryforward		5
Other accrued	1,016	2,547
Deferred revenue	57	317
Depreciation	309	297
Total long-term deferred tax assets	195,980	189,433
IPR&D	(15,476)
Total long-term deferred tax liabilities	(15,476)
Valuation allowance	(195,980)	(189,433)
Deferred tax liabilities, net	$ (15,476)

Note 21 - Selected Quarterly _3

Note 21 - Selected Quarterly Financial Data (Unaudited) - Schedule of Quarterly Financial Data (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended											9 Months Ended		12 Months Ended
	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
Grant revenue					$ 70	$ 695			$ 17	$ 1,147	$ 219			$ 765	$ 1,383
Total revenues				304	229	1,051	204	102	17	1,147	219	$ 198	$ 1,484	1,788	1,485
Research and development	3,792			2,368	2,197	2,879	3,118	2,418	3,062	5,483	6,413	10,547	8,194	10,562	17,376
Selling, general and administrative	3,395			2,787	1,500	1,208	1,926	1,182	1,749	1,804	1,922	9,990	4,634	7,421	6,657
Total expenses	7,187			5,155	3,697	4,087	5,044	3,600	4,811	7,287	8,335	20,537	12,828	17,983	24,033
Operating loss	(7,187)			(4,851)	(3,468)	(3,036)	(4,840)	(3,498)	(4,794)	(6,140)	(8,116)	(20,339)	(11,344)	(16,195)	(22,548)
Other income / (expense), net				(4,191)	(459)	(16)	328	5,971	(649)	(612)	(608)			(4,338)	4,102
Net (loss) / income	(7,126)	$ (6,437)	$ (6,537)	(9,042)	(3,927)	(3,052)	(4,512)	2,473	(5,443)	(6,752)	(8,724)	(20,100)	(11,491)	(20,533)	(18,446)
AEROSURF warrant dividend				(12,505)										(12,505)
Deemed dividend on preferred stock				(1,718)					(2,234)	(532)	(3,604)			(1,718)	(6,370)
Net (loss) / income attributable to common shareholders				$ (23,265)	$ (3,927)	$ (3,052)	$ (4,512)	$ 2,473	$ (7,677)	$ (7,284)	$ (12,328)			$ (34,756)	$ (24,816)
Net (loss) / income per common share - basic (in dollars per share)				$ (3.24)	$ (1.04)	$ (0.81)	$ (1.40)	$ 1.03	$ (10.53)	$ (14.37)	$ (27.40)			$ (7.74)	$ (24.14)
Net (loss) / income per common share - diluted (in dollars per share)				$ (3.24)	$ (1.04)	$ (0.81)	$ (1.40)	$ 0.97	$ (10.53)	$ (14.37)	$ (27.40)			$ (7.74)	$ (24.14)
Weighted average number of common shares outstanding - basic (in shares)				7,191	3,769	3,751	3,227	2,405	729	507	450			4,493	1,028
Weighted average number of common shares outstanding - diluted (in shares)				7,191	3,769	3,751	3,227	2,540	729	507	450			4,493	1,028
License [Member]
License revenue with affiliate				$ 304	$ 159	$ 356	$ 204	$ 102				$ 198	$ 719	$ 1,023	$ 102

Note 3 - Liquidity Risks and _2

Note 3 - Liquidity Risks and Management's Plans (Details Textual) - USD ($) $ in Thousands	Oct. 24, 2019	Sep. 30, 2019	Dec. 31, 2018	Dec. 31, 2017
Cash and Cash Equivalents, at Carrying Value, Ending Balance		$ 4,437	$ 11,187	$ 1,815
Liabilities, Current, Total		16,278	20,633	$ 11,760
Loans Payable, Current, Total		$ 7,800	$ 8,000
Common Stock, Shares Authorized		120,000,000	120,000,000	120,000,000
Preferred Stock, Shares Authorized		5,000,000	5,000,000	5,000,000
Common Stock, Capital Shares Available for Issuance		72,000,000	72,000,000
Preferred Stock, Capital Shares Available for Issuance		5,000,000	5,000,000
Subsequent Event [Member] | LPH II [Member] | LPH II Loan [Member]
Proceeds from Issuance of Debt	$ 1,000

Note 4 - Summary of Significa_3

Note 4 - Summary of Significant Accounting Policies (Details Textual) - USD ($) shares in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Dec. 31, 2017	Jan. 01, 2019	Dec. 01, 2017	Nov. 01, 2017
Foreign Currency Transaction Gain (Loss), before Tax, Total	$ 100,000	$ 0	$ 400,000	$ 0	$ 100,000	$ 0
Marketable Securities, Realized Gain (Loss), Total	14,000		75,000		0
Marketable Securities, Unrealized Gain (Loss), Total	(12,000)		0	$ 0	0
Liability for Contingent Milestone Payment, Noncurrent	15,000,000		$ 15,000,000		$ 15,000,000	$ 15,000,000
Number of Shares of Common Stock Potentially Issuable upon the Exercise of Stock Options and Warrants			15,600	1,300	14,400	1,000
Operating Lease, Right-of-Use Asset	1,566,000		$ 1,566,000
Operating Lease, Liability, Total	1,735,000		1,735,000
Accrued Liabilities, Current, Total	5,235,000		5,235,000		6,465,000	$ 4,134,000
Other Liabilities, Noncurrent, Total	106,000		106,000		175,000	100,000
Accounting Standards Update 2016-02 [Member]
Operating Lease, Right-of-Use Asset							$ 2,200,000
Operating Lease, Liability, Total							2,000,000
Accrued Liabilities, Current, Total							(72,000)
Other Liabilities, Noncurrent, Total							$ (139,000)
Deerfield Loan [Member]
Liability for Contingent Milestone Payment, Noncurrent	$ 15,000,000		$ 15,000,000		$ 15,000,000	$ 15,000,000
Deerfield Loan [Member] | Exchange and Termination Agreement [Member] | Deerfield Management, L.P. [Member]
Liability for Contingent Milestone Payment, Noncurrent								$ 15,000,000	$ 15,000,000

Note 4 - Summary of Significa_4

Note 4 - Summary of Significant Accounting Policies - Intangible Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018	Dec. 31, 2017
Indefinite intangible asset	$ 77,090	$ 77,090
Istaroxime Drug Candidate [Member]
Indefinite intangible asset	22,340	22,340
Rostafuroxin Drug Candidate [Member]
Indefinite intangible asset	$ 54,750	$ 54,750

Note 5 - License Revenue with_3

Note 5 - License Revenue with Affiliate - Disaggregation of Revenue (Details) - USD ($) $ in Thousands

3 Months Ended

9 Months Ended

12 Months Ended

Sep. 30, 2019

Dec. 31, 2018

Sep. 30, 2018

Jun. 30, 2018

Mar. 31, 2018

Dec. 31, 2017

Sep. 30, 2017

Jun. 30, 2017

Mar. 31, 2017

Sep. 30, 2019

Sep. 30, 2018

Dec. 31, 2018

Dec. 31, 2017

License [Member]

License revenue with affiliate

$ 304

$ 159

$ 356

$ 204

$ 102

$ 198

$ 719

$ 1,023

$ 102

Note 6 - Fair Value of Financ_3

Note 6 - Fair Value of Financial Instruments - Assets and Liabilities Measured at Fair Value (Details) - Fair Value, Recurring [Member] - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018	Dec. 31, 2017
Cash and cash equivalents	$ 4,437	$ 5,234	$ 1,815
Total Assets	4,591	25,317	2,040
Certificates of Deposit [Member]
Certificate of deposit	154	171	225
US Treasury Securities [Member]
Cash and cash equivalents		19,912
Cash and cash equivalents		19,912
Fair Value, Inputs, Level 1 [Member]
Cash and cash equivalents	4,437	5,234	1,815
Total Assets	4,591	25,317	2,040
Fair Value, Inputs, Level 1 [Member] | Certificates of Deposit [Member]
Certificate of deposit	154	171	225
Fair Value, Inputs, Level 1 [Member] | US Treasury Securities [Member]
Cash and cash equivalents		19,912
Cash and cash equivalents		19,912
Fair Value, Inputs, Level 2 [Member]
Cash and cash equivalents
Total Assets
Fair Value, Inputs, Level 2 [Member] | Certificates of Deposit [Member]
Certificate of deposit
Fair Value, Inputs, Level 2 [Member] | US Treasury Securities [Member]
Cash and cash equivalents
Cash and cash equivalents
Fair Value, Inputs, Level 3 [Member]
Cash and cash equivalents
Total Assets
Fair Value, Inputs, Level 3 [Member] | Certificates of Deposit [Member]
Certificate of deposit
Fair Value, Inputs, Level 3 [Member] | US Treasury Securities [Member]
Cash and cash equivalents
Cash and cash equivalents

Note 7 - Loans Payable (Details

Note 7 - Loans Payable (Details Textual) $ in Millions	Dec. 21, 2018USD ($)	Dec. 05, 2018USD ($)	May 30, 2019USD ($)	Apr. 30, 2019USD ($)	Mar. 31, 2018USD ($)	Jan. 31, 2018USD ($)	Sep. 30, 2017USD ($)	Mar. 31, 2019USD ($)	Sep. 30, 2019USD ($)	Sep. 30, 2018USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Dec. 31, 2018TWD ($)	Dec. 21, 2018TWD ($)	Nov. 19, 2018USD ($)	Nov. 16, 2018USD ($)	Nov. 02, 2018USD ($)	Oct. 19, 2018USD ($)	Sep. 27, 2018USD ($)	Sep. 12, 2018USD ($)	Aug. 29, 2018USD ($)	Aug. 14, 2018USD ($)	Sep. 30, 2017TWD ($)	Sep. 30, 2016USD ($)	Sep. 30, 2016TWD ($)
Repayments of Short-term Debt, Total									$ 820,000		$ 160,000
Short-term Debt, Total									7,782,000		$ 7,974,000
CVie Investments [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Total	$ 2,590,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt	3,453,000
Debt Payable to Lee's International [Member]
Debt Instrument, Interest Rate, Stated Percentage																4.00%
Debt Instrument, Face Amount																$ 3,500,000
Repayments of Short-term Debt, Total				$ 50,000				$ 450,000
Short-term Debt, Total									3,000,000
Debt Payable to Lee's International [Member] | Debt Maturing April 2019 [Member]
Debt Instrument, Face Amount																500,000
Debt Payable to Lee's International [Member] | Debt Maturing September 2019 [Member]
Debt Instrument, Face Amount																300,000
Debt Payable to Lee's International [Member] | Debt Maturing October 2019 [Member]
Debt Instrument, Face Amount																200,000
Debt Payable to Lee's International [Member] | Debt Maturing November 2019 [Member]
Debt Instrument, Face Amount																$ 2,500,000
Debt Payable to Lee's International [Member] | CVie Investments [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt	3,500,000													$ 106.2
Loan payable to Bank Direct Capital Finance [Member]
Loans Payable to Bank, Total									400,000
Loan payable to Bank Direct Capital Finance [Member] | Loans Payable [Member]
Debt Instrument, Interest Rate, Stated Percentage			5.35%
Debt Instrument, Face Amount			$ 700,000
Debt Instrument, Periodic Payment, Total			$ 80,000
Loan Payable Obligation Converted to LPH II [Member]
Debt Conversion, Original Debt, Amount	6,000,000
LPH [Member]
Proceeds from Issuance of Debt					$ 1,000,000	$ 1,500,000
Debt Instrument, Interest Rate, Stated Percentage											6.00%		6.00%
Debt Instrument, Face Amount		$ 600,000													$ 350,000		$ 500,000	$ 430,000	$ 500,000	$ 500,000	$ 480,000	$ 300,000
Short-term Debt, Total	6,000,000
LPH [Member] | Loan Payable Obligation Converted to LPH II [Member] | Debt Issued on January 2018 [Member]
Debt Conversion, Original Debt, Amount		1,500,000
LPH [Member] | Loan Payable Obligation Converted to LPH II [Member] | Debt Issued on March 2018 [Member]
Debt Conversion, Original Debt, Amount		$ 1,000,000
O-Bank Co., Ltd. [Member] | Revolving Credit Facility [Member]
Line of Credit Facility, Percent of Pledged Deposits Required							110.00%				110.00%		110.00%										110.00%
Line of Credit, Current									$ 4,500,000		$ 4,500,000		$ 138
O-Bank Co., Ltd. [Member] | Revolving Credit Facility [Member] | Taipei Interbank Offer Rate (TAIBOR) [Member]
Debt Instrument, Basis Spread on Variable Rate							0.91%				0.91%
O-Bank Co., Ltd. [Member] | Revolving Credit Facility [Member] | CVie Investments [Member]
Line of Credit Facility, Maximum Borrowing Capacity							$ 5,840,000																$ 180	$ 2,900,000	$ 90
O-Bank Co., Ltd. [Member] | CVie Investments [Member] | Revolving Credit Facility [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Total	$ 4,500,000				$ 4,500,000									$ 138

Note 8 - Restructured Debt Li_3

Note 8 - Restructured Debt Liability (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	Nov. 01, 2017	Dec. 31, 2018	Dec. 31, 2017	Sep. 30, 2019
Repayments of Long-term Debt, Total			$ 2,500
Liability for Contingent Milestone Payment, Noncurrent		15,000	15,000	$ 15,000
Deerfield Loan [Member]
Liability for Contingent Milestone Payment, Noncurrent		$ 15,000	$ 15,000	$ 15,000
Deerfield Loan [Member] | Exchange and Termination Agreement [Member] | Deerfield Management, L.P. [Member]
Extinguishment of Debt, Amount	$ 25,000
Class of Warrant or Right, Number of Warrants Cancelled	25,000
Class of Warrant or Right, Exercise Price of Cancelled Warrants	$ 786.80
Repayments of Long-term Debt, Total	$ 2,500
Stock Issued During Period, Shares, Cancellation of Debt and Warrant Obligations	71,111
Stock Issued During Period, Shares, Cancellation of Debt and Warrant Obligations, Percentage of Fully-diluted Shares Outstanding	2.00%
Liability for Contingent Milestone Payment, Noncurrent	$ 15,000

Note 8 - Restructured Debt Li_4

Note 8 - Restructured Debt Liability - Long-term Debt (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018	Dec. 31, 2017
Restructured debt liability - contingent milestone payments	$ 15,000	$ 15,000	$ 15,000
Deerfield Loan [Member]
Restructured debt liability - contingent milestone payments	$ 15,000	$ 15,000	$ 15,000

Note 9 - Stock Options and St_3

Note 9 - Stock Options and Stock-based Employee Compensation (Details Textual) - The 2011 Long-term Incentive Plan [Member]	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period		3 years
Stock-based Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period	3 years
Restricted Stock Units (RSUs) [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period	180 days
Restricted Stock Units (RSUs) [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period	1 year 180 days

Note 9 - Stock Options and St_4

Note 9 - Stock Options and Stock-based Employee Compensation - Summary of Stock Option Activity (Details) - $ / shares shares in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Shares Outstanding, Beginning Balance (in shares)	4,417	84
Weighted Average Exercise Price, Outstanding, at Beginning Period (in dollars per share)	$ 6.73	$ 163.20
Shares Granted (in shares)	1,144	4,337
Weighted Average Exercise Price, Granted (in dollars per share)	$ 4.20	$ 4.22
Shares Forfeited or Expired (in shares)	(5)	(4)
Weighted Average Exercise Price, Forfeited or Expired (in dollars per share)	$ 467.57	$ 617.75
Shares Outstanding, Ending Balance (in shares)	5,556	4,417
Weighted Average Exercise Price, Outstanding, at Ending Period (in dollars per share)	$ 5.80	$ 6.73
Weighted Average Remaining Contractual Life, Outstanding (Year)	9 years 73 days	9 years 328 days
Shares Vested and Exercisable (in shares)	70	63
Weighted Average Exercise Price, Vested and Exercisable (in dollars per share)	$ 128.45	$ 171.87
Weighted Average Remaining Contractual Life, Vested and Exercisable (Year)	6 years 109 days	6 years 182 days
Vested and expected to vest (in shares)	5,245	4,243
Weighted Average Exercise Price, Vested and Expected to Vest (in dollars per share)	$ 5.79	$ 6.78
Weighted Average Remaining Contractual Life, Vested and Expected to Vest (Year)	9 years 73 days	9 years 328 days

Note 9 - Stock Options and St_5

Note 9 - Stock Options and Stock-based Employee Compensation - Summary of Restricted Stock Units Activity (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares shares in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018	Dec. 31, 2017
Unvested, Beginning Balance (in shares)	151	190
Unvested, Beginning Balance (in dollars per share)	$ 4.29	$ 4.33
Awarded (in shares)	249	56
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 3.95	$ 4.22	$ 4.33
Vested (in shares)	(95)	(95)
Vested (in dollars per share)	$ 3.95	$ 4.33
Cancelled (in shares)	(144)
Cancelled (in dollars per share)	$ 4.33
Unvested, Ending Balance (in shares)	161	151	190
Unvested, Ending Balance (in dollars per share)	$ 4.04	$ 4.29	$ 4.33

Note 9 - Stock Options and St_6

Note 9 - Stock Options and Stock-based Employee Compensation - Stock Options Valuation Assumptions (Details)	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018	Dec. 31, 2017
Weighted average expected volatility	95.00%	93.00%	79.00%
Weighted average expected term (Year)	6 years 219 days	7 years	6 years 219 days
Weighted average risk-free interest rate	2.60%	2.70%	2.20%
Expected dividends

Note 9 - Stock Options and St_7

Note 9 - Stock Options and Stock-based Employee Compensation - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
Share-based Payment Arrangement, Expense	$ 1,939	$ 145	$ 5,208	$ 703	$ 955	$ 1,561
Research and Development Expense [Member]
Share-based Payment Arrangement, Expense	574	29	1,613	169	$ 232	$ 837
General and Administrative Expense [Member]
Share-based Payment Arrangement, Expense	$ 1,365	$ 116	$ 3,595	$ 534

Note 10 - Leases (Details Textu

Note 10 - Leases (Details Textual)	Sep. 30, 2019
Operating Lease, Weighted Average Remaining Lease Term	2 years 146 days
Warrington, Pennsylvania [Member]
Operating Lease, Weighted Average Remaining Lease Term	3 years

Note 10 - Leases - Lease Costs

Note 10 - Leases - Lease Costs (Details) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2019USD ($)	Sep. 30, 2019USD ($)
Operating lease cost	$ 212	$ 677
Variable lease cost	5	17
Total lease cost	217	694
Operating cash flows used for operating leases	227	721
Operating lease liabilities arising from obtaining right-of-use assets	$ 232	$ 364
Weighted average remaining lease term (in years) (Year)	2 years 146 days	2 years 146 days
Weighted average incremental borrowing rate	9.00%	9.00%

Note 10 - Leases - Future Minim

Note 10 - Leases - Future Minimum Lease Payments (Details) $ in Thousands	Sep. 30, 2019USD ($)
2019 (excluding the nine months ended September 30, 2019)	$ 230
2020	849
2021	638
2022	179
2023	23
Thereafter
Total lease payments	1,919
Less imputed interest	(184)
Total operating lease liabilities at September 30, 2019	$ 1,735

Note 11 - Subsequent Event (Det

Note 11 - Subsequent Event (Details Textual) - LPH II Loan [Member] - Subsequent Event [Member] - LPH II [Member] - USD ($) $ in Millions	Oct. 24, 2019	Oct. 28, 2019
Proceeds from Issuance of Debt	$ 1
Debt Instrument, Interest Rate, Effective Percentage		6.00%